Use of mir-15a-5p in treatment of fundus diseases
By administering miR-15a-5p or modifying miR-15a-5p locally, VEGF and TGF-β1 are inhibited, solving the multi-target problem that existing technologies cannot effectively treat fundus diseases, and achieving the effects of inhibiting retinal neovascularization, restoring visual function and protecting neuron.
Patent Information
- Application Number
- PCT/CN2024/073634
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-21
- Filing Date
- 2024-01-23
- Publication Date
- 2024-12-26
AI Technical Summary
In treating fundus diseases such as retinopathy of prematurity and diabetic retinopathy, current technologies are inadequate. Anti-VEGF therapy cannot effectively improve retinal nerve damage and functional decline, laser therapy is destructive and cannot completely prevent neovascularization, and there is a lack of effective multi-target treatment methods.
miR-15a-5p or modified miR-15a-5p can be administered topically to inhibit VEGF and TGF-β1, promote retinal cell uptake, inhibit pathological angiogenesis, reduce the expression of inflammatory factors, alleviate fibrosis and promote nerve damage repair. miRNA can be delivered into the intraocular space using viral or non-viral vectors.
It effectively inhibits neovascularization of the retina and choroid, restores retinal blood supply, reduces non-perfusion areas, protects the optic nerve, reduces inflammation, improves visual function, and has a better safety profile than anti-VEGF drugs such as ranibizumab.
Smart Images

Figure CN2024073634_26122024_PF_FP_ABST
Abstract
Description
Application of miR-15a-5p in the treatment of fundus diseases Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to the use of miRNA or modified miRNA (especially miR-15a-5p or modified miR-15a-5p) in treating fundus diseases. Background Art
[0002] The fundus is the most important physiological structure of the eyeball, comprising the choroid, retina, and vitreous humor. The retina, densely packed with blood vessels and nerves, is the primary structure responsible for vision and plays a crucial physiological role. Pathogenic factors such as elevated blood sugar or hypoxia can cause retinal damage, leading to decreased vision. For example, retinopathy of prematurity (ROP) is a common blinding fundus disease in premature infants. Its pathological mechanism is retinal vascular degeneration and persistent, extensive neovascularization caused by neonatal oxygen inhalation. During retinal development, these vascular abnormalities simultaneously lead to neuronal degeneration and degeneration, significantly impacting infant retinal development. Current treatment involves intravitreal injection of monoclonal antibodies against vascular endothelial growth factor (VEGF). However, these drugs have a single target and are unable to ameliorate retinal neurodegeneration or reduce retinal inflammation. Furthermore, because VEGF is an important neurotrophic factor, anti-VEGF therapy can lead to further damage to retinal neurons and decreased retinal function. Diabetic retinopathy (DR), which is prevalent among working-age individuals, is also a microvascular disease characterized by neovascularization and neurodegeneration. The causative factor is persistently elevated blood sugar, but the subsequent pathological mechanisms are complex. Existing treatments involve laser photocoagulation during the non-proliferative phase to destroy the peripheral retina to reduce vascular leakage and lower retinal oxygen consumption. However, laser therapy is somewhat destructive and cannot completely prevent the formation of new blood vessels. During the proliferative phase, intravitreal injection of anti-VEGF monoclonal antibodies is generally used to inhibit new blood vessels, or vitrectomy is performed. As previously mentioned, anti-VEGF therapy does not improve retinal nerve damage and function.
[0003] MicroRNAs (miRNAs) are a class of non-coding, single-stranded RNA molecules approximately 22 nucleotides long, encoded by endogenous genes. They participate in post-transcriptional gene expression regulation in plants and animals. Their primary characteristics are their natural presence in the human body, multi-target regulation, and rich biological functions. Among them, miR-15a-5p is closely associated with the development and progression of numerous diseases.
[0004] Patent document: CN112575088B discloses the use of a plasma exosomal miRNA biomarker in the preparation of a kit for screening and diagnosing endometrial cancer. The biomarker is a combination of miR-15a-5p, miR-106b-5p and miR-107.
[0005] Patent document: CN109414459B discloses that exosomes containing miRNAs such as miR-15a-5p can promote wound healing.
[0006] Patent document: CN113943800A discloses the use of a reagent for detecting exosomal miR-15a-5p in the preparation of a thyroid cancer iodine resistance screening kit.
[0007] Patent document: CN110205377A discloses a method for early assessment of Kawasaki disease risk based on miRNA molecular markers. The miRNA molecular markers are miR-30c-5p, miR-26a-5p, miR-27a-3p, miR-15a-5p, miR-186-5p, let-7g-5p, miR-941, miR-92a-3p, miR-22-3p, miR-151a-3p, miR-140-3p, miR-199a-3p, and miR-4433b-5p.
[0008] Currently, there is little research on the application and mechanism of single biological component miR-15a-5p in fundus diseases.
[0009] Summary of the Invention
[0010] In order to make up for the shortcomings of the existing technology, this application demonstrates the effectiveness of miRNA in treating fundus diseases, especially miR-15a-5p or modified miR-15a-5p has biological activity, can be absorbed by cells in vitro, or absorbed by retinal cells in vivo, and quickly exert biological effects. Through local administration, the miR-15a-5p or modified miR-15a-5p can inhibit pathological neovascularization, promote the recovery of non-perfused areas, reduce the expression of retinal inflammatory factors, alleviate retinal fibrosis and promote nerve damage repair. In addition, the experiment determined that the actual fragment in the miRNA that plays a role is ACGACGAU (SEQ ID NO: 10), and the mutated or modified miR-15a-5p still has a good effect. This achievement has very good application and research value in the field of biomedicine.
[0011] The specific plan is as follows:
[0012] In a first aspect, the present invention provides use of a miRNA and / or modified miRNA and / or a vector comprising a nucleic acid transcribed into miRNA in the preparation of a product for treating and / or preventing fundus diseases.
[0013] The nucleotide sequence of the miRNA includes ACGACGAU (SEQ ID NO: 10).
[0014] Preferably, the nucleotide sequence of the miRNA comprises SEQ ID NO: 10 and has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more identity with the nucleotide sequence of SEQ ID NO: 1.
[0015] Preferably, the nucleotide sequence of the miRNA includes SEQ ID NO: 10, and has a nucleotide sequence comprising substitutions, deletions or insertions of one or more nucleotides compared to the nucleotide sequence of SEQ ID NO: 1, preferably a nucleotide sequence comprising substitutions, deletions or insertions of no more than ten, nine, eight, seven, six, five, four, three, two or one nucleotide.
[0016] Preferably, the miRNA is miR-15a-5p.
[0017] In a specific embodiment of the present invention, the nucleotide sequence of the miRNA is SEQ ID NO: 1.
[0018] The fundus disease is a fundus disease that is beneficial for prevention and / or treatment by inhibiting VEGF and / or TGF-β1, preferably a fundus disease that is beneficial for prevention and / or treatment by inhibiting both VEGF and TGF-β1.
[0019] The fundus disease is selected from one or more of vitreous lesions, retinal lesions, optic neuropathy or choroidal lesions.
[0020] Preferably, the fundus disease is selected from one or more of retinopathy of prematurity, retinal neovascularization disease, choroidal neovascularization disease or diabetic retinopathy.
[0021] The miRNA and / or modified miRNA and / or vector comprising a nucleic acid transcribed into the miRNA targets and / or regulates VEGF and / or TGF-β1, preferably targeting both VEGF and TGF-β1. The regulation is upregulation or downregulation. Preferably, the regulation of TGF-β1 comprises or is by inhibiting Smad2. Preferably, the regulation of VEGF comprises inhibiting VEGF.
[0022] Preferably, the miRNA and / or modified miRNA and / or vector comprising a nucleic acid transcribed into miRNA comprises a domain targeting VEGF and / or TGF-β1 (eg, SEQ ID NO: 10).
[0023] Preferably, the sequence of the miRNA comprises modifications, such as modifications at the bases.
[0024] Wherein, SEQ ID NO: 1 comprises or is UAGCAGCACAUAAUGGUUUGUG.
[0025] The miRNA or its mimic comprises a sense strand and an antisense strand. The sense strand comprises or is SEQ ID NO: 1 or has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or 99% or more homology to the nucleotide sequence of SEQ ID NO: 1, or comprises a nucleotide sequence of substitution, deletion or insertion of one or more nucleotides, and the antisense strand comprises or is CACAAACCAUUAUGUGCUGCUA (SEQ ID NO: 6) or has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or 99% or more homology to the nucleotide sequence of SEQ ID NO: 1, The nucleotide sequence of NO:6 has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more 99% homology or contains a nucleotide sequence of substitution, deletion or insertion of one or more nucleotides.
[0026] The product comprises miRNA and / or modified miRNA and / or miRNA mimics, or a vector comprising miRNA and / or modified miRNA and / or miRNA mimics (the vector may be any vector that encapsulates, transcribes or expresses miRNA).
[0027] The vector is a viral vector or a non-viral vector.
[0028] Preferably, the viral vector comprises one or more of a lentiviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a poxvirus vector or a herpesvirus vector.
[0029] Preferably, the non-viral vector comprises one or more of liposomes, lipid nanoparticles, polymers, polypeptides, antibodies, aptamers or N-acetylgalactosamine.
[0030] The sequence of the miRNA may contain modifications, such as modifications at the bases.
[0031] Modified miRNAs include modifications at the bases.
[0032] The base modification is located in the sense strand and / or the antisense strand.
[0033] Preferably, the modifications performed on the base include one or more of cholesterol modification at the 3' end, two sulfo-skeleton modifications at the 5' end, four sulfo-skeleton modifications at the 3' end, or full-chain methoxy modification.
[0034] The product contains a sense strand and an antisense strand.
[0035] Preferably, the sense strand and / or antisense strand contains dangling bases.
[0036] The dangling base is located at the 3' end of the sense strand and / or the antisense strand.
[0037] The dangling base is a deoxynucleoside. Preferably, the dangling base is dTdT, dTdC, or dUdU. For example, the sense strand of the miRNA or its mimic may be UAGCAGCACAUAAUGGUUUGUGdTdT (SEQ ID NO: 7), and the antisense strand may be CACAAACCAUUAUGUGCUGCUAdTdT (SEQ ID NO: 8).
[0038] The sense strand and / or antisense strand contained in the miRNA or its mimics undergoes one or more of full-chain methoxy modification, 3'-end cholesterol modification, 5'-end thio backbone modification or 3'-end thio backbone modification.
[0039] In a specific embodiment of the present invention, the antisense strand of the miRNA or its mimic is modified with methoxy groups throughout the entire strand, cholesterol at the 3' end, two thio backbones at the 5' end, and four thio backbones at the 3' end.
[0040] In a specific embodiment of the present invention, the sense strand comprises or is SEQ ID NO: 1 or a nucleotide sequence having 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or 99% or more homology to the nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence comprising substitution, deletion or insertion of one or more nucleotides, and the antisense strand comprises SEQ ID NO: 6 modified with two thio backbones at the 5' end, four thio backbones at the 3' end, cholesterol modified at the 3' end and methoxy modified throughout the chain. The nucleotide sequence of NO:6 has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more 99% homology or contains a nucleotide sequence of substitution, deletion or insertion of one or more nucleotides.
[0041] The treatment and / or prevention of fundus diseases is selected from one or more of the following: inhibiting the activity of retinal vascular endothelial cells (HRMECs), inhibiting the proliferation of HRMECs (especially weakening the proliferation of HRMECs induced by VEGF), inhibiting the phosphorylation of Smad2, inhibiting the expression of total Smad2, inhibiting fibrosis, inhibiting the expression of VEGF, inhibiting retinal inflammation, anti-angiogenesis or promoting the recovery of non-perfused areas, improving retinal thinning, restoring visual function or promoting nerve damage repair.
[0042] Preferably, the anti-angiogenesis includes inhibiting retinal neovascularization and / or choroidal neovascularization.
[0043] The treatment and / or prevention of fundus diseases comprises administering miRNA and / or modified miRNA or miRNA mimics and / or administering a vector comprising miRNA and / or modified miRNA or miRNA mimics (eg, a vector comprising a nucleic acid transcribed into miRNA) to a subject in need thereof.
[0044] The administration site can be an intraocular space or cavity of the subject, such as one or more of the aqueous humor in the anterior chamber, the suspensory ligament, the ciliary body, the ciliary body and muscles, the lens or iris, the vitreous body, the retina, the choroid or the optic nerve.
[0045] In a second aspect, the present invention provides a vector comprising a nucleic acid that is transcribed into miRNA or a mimic thereof.
[0046] The nucleotide sequence of the miRNA includes SEQ ID NO: 10.
[0047] Preferably, the nucleotide sequence of the miRNA comprises SEQ ID NO: 10 and has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more identity with the nucleotide sequence of SEQ ID NO: 1.
[0048] Preferably, the nucleotide sequence of the miRNA includes SEQ ID NO: 10, and has a nucleotide sequence comprising substitutions, deletions or insertions of one or more nucleotides compared to the nucleotide sequence of SEQ ID NO: 1, preferably a nucleotide sequence comprising substitutions, deletions or insertions of no more than ten, nine, eight, seven, six, five, four, three, two or one nucleotide.
[0049] Preferably, the miRNA is miR-15a-5p.
[0050] In a specific embodiment of the present invention, the nucleotide sequence of the miRNA is SEQ ID NO: 1.
[0051] The miRNA sequence includes modifications, such as base modifications, located on the sense strand and / or antisense strand, preferably including one or more of the following: cholesterol modification at the 3' end, two sulfo-backbone modifications at the 5' end, four sulfo-backbone modifications at the 3' end, or full-strand methoxy modification.
[0052] The nucleic acid transcribed into miRNA comprises TAGCAGCA (SEQ ID NO: 11).
[0053] Preferably, the nucleic acid transcribed into miRNA comprises SEQ ID NO: 11 and has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more identity with the nucleotide sequence of SEQ ID NO: 9.
[0054] Preferably, the nucleic acid transcribed into miRNA comprises SEQ ID NO: 11, and has a nucleotide sequence comprising substitutions, deletions or insertions of one or more nucleotides compared to the nucleotide sequence of SEQ ID NO: 9, preferably a nucleotide sequence comprising substitutions, deletions or insertions of no more than ten, nine, eight, seven, six, five, four, three, two or one nucleotide.
[0055] In a specific embodiment of the present invention, the nucleic acid transcribed into miRNA is SEQ ID NO: 9.
[0056] The miRNA or its mimics comprises a sense strand and an antisense strand. The sense strand comprises SEQ ID NO: 1, or a nucleotide sequence having 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or 99% or more homology to the nucleotide sequence of SEQ ID NO: 1, or comprising a substitution, deletion or insertion of one or more nucleotides; the antisense strand comprises SEQ ID NO: 6, or a nucleotide sequence having 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or 99% or more homology to the nucleotide sequence of SEQ ID NO: 6, or comprising a substitution, deletion or insertion of one or more nucleotides.
[0057] The sense strand and / or antisense strand contain dangling bases.
[0058] The dangling base is located at the 3' end of the sense strand and / or the antisense strand.
[0059] The dangling bases are deoxynucleosides.
[0060] The hanging base is dTdT, dTdC or dUdU.
[0061] The vector is a viral vector or a non-viral vector.
[0062] The viral vector includes one or more of a lentiviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a poxvirus vector or a herpesvirus vector.
[0063] The non-viral vector comprises one or more of liposomes, lipid nanoparticles, polymers, polypeptides, antibodies, aptamers or N-acetylgalactosamine.
[0064] The third aspect of the present invention provides a modified miR-15a-5p or miR-15a-5p mimic.
[0065] The modified miR-15a-5p includes modifications on the bases.
[0066] The base modification is located in the antisense strand, preferably including one or more of the following: cholesterol modification at the 3' end, two thio-backbone modifications at the 5' end, four thio-backbone modifications at the 3' end, or methoxy modification throughout the entire strand.
[0067] The sense chain and / or antisense chain contained in the miR-15a-5p or its mimics undergoes one or more of full-chain methoxy modification, 3'-end cholesterol modification, 5'-end thio backbone modification or 3'-end thio backbone modification.
[0068] In a specific embodiment of the present invention, the antisense strand of miR-15a-5p or its mimics is modified with full-chain methoxy, 3'-end cholesterol, 5'-end two thio backbones and 3'-end four thio backbones.
[0069] In a specific embodiment of the present invention, the sense strand comprises SEQ ID NO: 1 or a nucleotide sequence having 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or 99% or more homology to the nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence comprising substitution, deletion or insertion of one or more nucleotides, and the antisense strand comprises SEQ ID NO: 6 modified with two thio backbones at the 5' end, four thio backbones at the 3' end, cholesterol modified at the 3' end and methoxy modified throughout the chain. The nucleotide sequence of NO:6 has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more 99% homology or contains a nucleotide sequence of substitution, deletion or insertion of one or more nucleotides.
[0070] In a fourth aspect, the present invention provides a drug or pharmaceutical composition comprising the above-mentioned miRNA and / or modified miRNA and / or miRNA mimics and / or the above-mentioned vector comprising nucleic acid transcribed into miRNA or miRNA mimics, and pharmaceutically acceptable excipients.
[0071] The nucleotide sequence of the miRNA includes ACGACGAU (SEQ ID NO: 10).
[0072] Preferably, the nucleotide sequence of the miRNA comprises SEQ ID NO: 10 and has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more identity with the nucleotide sequence of SEQ ID NO: 1.
[0073] Preferably, the nucleotide sequence of the miRNA includes SEQ ID NO: 10, and has a nucleotide sequence comprising substitutions, deletions or insertions of one or more nucleotides compared to the nucleotide sequence of SEQ ID NO: 1, preferably a nucleotide sequence comprising substitutions, deletions or insertions of no more than ten, nine, eight, seven, six, five, four, three, two or one nucleotide.
[0074] Preferably, the miRNA is miR-15a-5p.
[0075] In a specific embodiment of the present invention, the nucleotide sequence of the miRNA is SEQ ID NO: 1.
[0076] Modified miRNAs include modifications at the bases.
[0077] Preferably, the modifications performed on the base include one or more of cholesterol modification at the 3' end, two sulfo-skeleton modifications at the 5' end, four sulfo-skeleton modifications at the 3' end, or full-chain methoxy modification.
[0078] The medicine or pharmaceutical composition can treat fundus diseases.
[0079] The pharmaceutical composition may also contain other nucleic acids, polypeptides, proteins, compounds, etc. for treating or preventing fundus diseases or nucleic acids, polypeptides, proteins, compounds, etc. for reducing side effects.
[0080] The drug or pharmaceutical composition can be administered by any suitable route, such as enteral administration (e.g., oral) or parenteral administration (e.g., intravenous, intramuscular, subcutaneous, intradermal, intraorgan, intranasal, intraocular, instillation, intracerebral, intrathecal, transdermal, intrarectal, etc.).
[0081] The drug or pharmaceutical composition can be in any suitable dosage form, such as a dosage form for gastrointestinal administration or a dosage form for parenteral administration, preferably including but not limited to tablets, pills, powders, granules, capsules, lozenges, syrups, liquids, emulsions, microemulsions, suspensions, injections, sprays, aerosols, powder mists, lotions, ointments, plasters, pastes, patches, eye drops, nasal drops, sublingual tablets, suppositories, aerosols, effervescent tablets, pills, gels, and the like.
[0082] Various dosage forms of the drug or pharmaceutical composition can be prepared according to conventional production methods in the pharmaceutical field.
[0083] The drug or pharmaceutical composition may contain the miRNA, modified miRNA, or a vector containing the miRNA or modified miRNA in an amount of 0.01-99.5% (e.g., 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%) by weight.
[0084] The medicine or pharmaceutical composition can be a human medicine or a veterinary medicine.
[0085] In a fifth aspect, the present invention provides a method for treating and / or preventing fundus diseases, which comprises administering to a subject in need thereof an effective amount of miRNA and / or modified miRNA and / or miRNA mimics and / or a vector and / or pharmaceutical composition comprising miRNA or modified miRNA or miRNA mimics.
[0086] The nucleotide sequence of the miRNA includes ACGACGAU (SEQ ID NO: 10).
[0087] Preferably, the nucleotide sequence of the miRNA comprises SEQ ID NO: 10 and has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more identity with the nucleotide sequence of SEQ ID NO: 1.
[0088] Preferably, the nucleotide sequence of the miRNA includes SEQ ID NO: 10, and has a nucleotide sequence comprising substitutions, deletions or insertions of one or more nucleotides compared to the nucleotide sequence of SEQ ID NO: 1, preferably a nucleotide sequence comprising substitutions, deletions or insertions of no more than ten, nine, eight, seven, six, five, four, three, two or one nucleotide.
[0089] Preferably, the miRNA is miR-15a-5p.
[0090] In a specific embodiment of the present invention, the nucleotide sequence of the miRNA is SEQ ID NO: 1.
[0091] The fundus disease is a fundus disease that can be prevented and / or treated by inhibiting VEGF and / or TGF-β1.
[0092] The fundus disease is selected from one or more of vitreous lesions, retinal lesions, optic neuropathy or choroidal lesions.
[0093] The fundus diseases include, but are not limited to, one or more of retinopathy of prematurity, retinal neovascularization disease, choroidal neovascularization disease or diabetic retinopathy.
[0094] The miRNA or its mimic comprises a sense strand and an antisense strand, wherein the sense strand comprises SEQ ID NO: 1 or a nucleotide sequence having 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or 99% or more homology to the nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence having substitution, deletion or insertion of one or more nucleotides, and the antisense strand comprises SEQ ID NO: 6 or a nucleotide sequence having 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more homology to the nucleotide sequence of SEQ ID NO: 1, The nucleotide sequence of NO:6 has 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more 99% homology or contains a nucleotide sequence of substitution, deletion or insertion of one or more nucleotides.
[0095] The modified miRNA includes base modifications, including one or more of the following: 3'-end cholesterol modification, 5'-end two-sulfo backbone modification, 3'-end four-sulfo backbone modification, or full-chain methoxy modification.
[0096] The treatment and / or prevention of fundus diseases is selected from one or more of the following: inhibiting HRMECs activity, inhibiting HRMECs proliferation (especially weakening VEGF-induced HRMECs proliferation), inhibiting Smad2 phosphorylation, inhibiting total Smad2 expression, inhibiting fibrosis, inhibiting VEGF expression, inhibiting retinal inflammation, anti-angiogenesis or promoting recovery of non-perfused areas, improving retinal thinning, restoring visual function or promoting nerve damage repair.
[0097] Preferably, the anti-angiogenesis includes inhibiting retinal neovascularization and / or choroidal neovascularization.
[0098] Preferably, the method comprises administering 0.5 μg-5 mg (e.g., 0.5 μg, 1 μg, 2 μg, 3 μg, 4 μg, 5 μg, 10 μg, 20 μg, 50 μg, 100 μg, 150 μg, 200 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950 μg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg) of the miRNA, modified miRNA, miRNA mimic, vector comprising the miRNA or modified miRNA or miRNA mimic, or the above-mentioned drug or pharmaceutical composition to each eye.
[0099] Preferably, the method comprises administering to one or more of the intraocular space or cavity of the subject, such as the aqueous humor in the anterior chamber, the suspensory ligament, the ciliary body, the ciliary body and muscles, the lens or iris, the vitreous body, the retina, the choroid or the optic nerve.
[0100] In vivo validation of modified miRNAs (e.g., modified mir-15a-5p, whose antisense base modifications include cholesterol at the 3' end, two thiolate modifications at the 5' end, four thiolate modifications at the 3' end, and full-chain methoxy modifications, i.e., Agomir-15a-5p) was compared with the clinically effective anti-VEGF drug ranibizumab. The results showed that its inhibitory effects on retinal and choroidal neovascularization were comparable to those of ranibizumab, and its superiority over ranibizumab lies in the following four aspects: first, it inhibits neovascularization while promoting retinal blood flow recovery and reducing the area of retinal non-perfused areas; second, it has optic neuroprotective effects; third, it inhibits retinal inflammatory factors and inflammatory mediators; and fourth, it reduces retinal fibrosis.
[0101] The term "pharmaceutically acceptable" as used herein means that the pharmaceutical composition neither significantly stimulates the organism nor inhibits the biological activity and properties of the active substance of the administered product.
[0102] The "pharmaceutically acceptable excipients" mentioned in the present invention include, but are not limited to, one or more of carriers, excipients, diluents, wetting agents, fillers, binders, lubricants, disintegrants, antioxidants, buffers, suspending agents, solubilizers, thickeners, stabilizers, flavoring agents or preservatives.
[0103] As used herein, "treating" means slowing, interrupting, preventing, controlling, stopping, alleviating, or reversing the progression or severity of a sign, symptom, disorder, condition, or disease after the disease has begun to develop, but does not necessarily involve the complete elimination of all disease-associated signs, symptoms, conditions, or disorders.
[0104] The "effective amount" of the present invention refers to the amount or dosage of the miRNA, miRNA mimics, modified miRNA, drug or pharmaceutical composition of the present invention that provides the desired treatment or prevention after single or multiple doses are administered to an individual or organ.
[0105] The term "prevention" used in the present invention refers to a method implemented to prevent or delay the occurrence of a disease, disorder or symptom in the body.
[0106] The "subject" of the present invention can be a human or a non-human mammal, and the non-human mammal can be a wild animal, a zoo animal, a commercial animal, a pet, an experimental animal, etc. Preferably, the non-human mammal includes but is not limited to pigs, cattle, sheep, horses, donkeys, foxes, raccoon dogs, minks, camels, dogs, cats, rabbits, mice (e.g., rats, mice, guinea pigs, hamsters, gerbils, chinchillas, squirrels), monkeys, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0107] Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings, in which:
[0108] Figure 1: After transfection of miR-15a-5p mimic control, mimic, inhibitor control, and inhibitor into retinal vascular endothelial cells, miR-15a-5p expression in the cells was measured. The mimic increased miR-15a-5p expression, while the inhibitor decreased it.
[0109] Figure 2: Effects of different concentrations of VEGF on retinal endothelial cell proliferation. 10 ng / ml of VEGF can induce abnormal cell proliferation.
[0110] Figure 3: Effects of different concentrations of VEGF on the relative expression of miR-15a-5p in retinal endothelial cells. 10 ng / ml VEGF did not affect the expression of miR-15a-5p in cells.
[0111] Figure 4: CCK-8 assay to detect the effect of miR-15a-5p on cell proliferation. miR-15a-5p mimics attenuated VEGF-induced pathological proliferation of retinal vascular endothelial cells.
[0112] Figure 5: Cell scratch assay to detect the effect of miR-15a-5p on cell proliferation ability.
[0113] Figure 6: Quantitative statistical analysis of cell scratches. miR-15a-5p mimics reduce VEGF-induced pathological proliferation of retinal endothelial cells.
[0114] Figure 7: Transwell assay to detect the effect of miR-15a-5p on cell migration ability.
[0115] Figure 8: Quantitative statistical analysis of the number of cell migration in the Transwell experiment. miR-15a-5p mimics reduced VEGF-induced pathological migration of retinal vascular endothelial cells.
[0116] Figure 9: Tube formation assay to detect the effect of miR-15a-5p on the tube-forming ability of cells in vitro.
[0117] Figure 10: Quantitative statistical analysis of the total length of the vascular lumen formed by cells in the tube formation experiment. miR-15a-5p mimics reduce VEGF-induced retinal vascular endothelial cell tube formation.
[0118] Figure 11: Quantitative statistical analysis of the number of vascular tube nodes formed by cells in the tube formation experiment. miR-15a-5p mimics reduce VEGF-induced vascular tube formation in retinal endothelial cells.
[0119] Figure 12: Differences in mouse retinal uptake of modified (Agomir) and unmodified (mimic) miR-15a-5p mimics. * indicates P < 0.05 for the mimic group compared to the control group, ** indicates P < 0.01; @ indicates P < 0.05 for the modified mimic group compared to the control group, @@@ indicates P < 0.001, and @@@@ indicates P < 0.0001; # indicates P < 0.05 for the mimic group compared to the modified mimic group, #### indicates P < 0.0001.
[0120] Figure 13: Flowchart of the oxygen-induced mouse retinal neovascularization model. P represents the day after birth of the mouse.
[0121] Figure 14: Expression levels of retinal miR-15a-5p during development of oxygen-induced retinal neovascularization in mice. The normoxia group represents untreated mice, while the hyperoxia group represents the neovascularization model group.
[0122] Figure 15: Effects of different doses of miR-15a-5p mimics on oxygen-induced retinal neovascularization. The normoxia group represents untreated mice, the hyperoxia group represents the neovascularization model, and the mimic is Agomir.
[0123] Figure 16: Statistical graph showing the effects of different doses of miR-15a-5p mimics on oxygen-induced retinal neovascularization. The normoxia group represents untreated mice, the hyperoxia group represents the neovascularization model group, the mimic represents Agomir, and the mimic control group represents scrambled Agomir.
[0124] Figure 17: Effects of different doses of anti-VEGF drugs on oxygen-induced retinal neovascularization. A is the staining image, and B is the statistical graph. The normoxia group represents untreated mice, while the hyperoxia group represents the neovascularization model.
[0125] Figure 18: Distribution and persistence of Agomir-15a-5p in the retina after administration. (A) Representative images of CY3-labeled Agomir-15a-5p in the retina. (B) Quantification of the fluorescence intensity of CY3-labeled Agomir-15a-5p. (C) Expression trends of Agomir-15a-5p in the OIR retina after injection.
[0126] Figure 19: Schematic representation of the effect of 1 μg of miR-15a-5p mimics on oxygen-induced retinal neovascularization. Normoxia (column 1) represents untreated mice, hyperoxia (columns 2-4) represents the neovascularization model group, the mimic is Agomir, the mimic control is scrambled Agomir, and the anti-VEGF is ranibizumab.
[0127] Figure 20: Statistical graph of neovascularization area in retinal neovascularization induced by oxygen after treatment with 1 μg of miR-15a-5p mimics. Normoxia represents untreated mice, hyperoxia represents the neovascularization model group, mimics represent Agomir, mimic control represents scrambled Agomir, and the VEGF monoclonal antibody represents ranibizumab.
[0128] Figure 21: Statistical graph of the non-perfused area in oxygen-induced retinal neovascularization treated with 1 μg of miR-15a-5p mimic. Normoxia represents untreated mice, hyperoxia represents the neovascularization model group, mimic represents Agomir, mimic control represents scrambled Agomir, and the VEGF monoclonal antibody represents ranibizumab.
[0129] Figure 22: Schematic diagram of the structure of adeno-associated virus containing miR-15a-5p.
[0130] FIG23 : Schematic diagram of retinal infection with adeno-associated virus containing miR-15a-5p.
[0131] Figure 24: PCR results show the overexpression of miR-15a-5p in the retina after adeno-associated virus infection. OIR-AAV-NC is the control virus injection group, and OIR-AAV-15a is the injection group containing miR-15a-5p.
[0132] Figure 25: Schematic diagram of the therapeutic effect of adeno-associated virus containing miR-15a-5p on retinal neovascularization and non-perfused areas. OIR-AAV-NC is the control virus injection group, and OIR-AAV-15a is the adeno-associated virus injection containing miR-15a-5p.
[0133] FIG26 : Statistical results of the therapeutic effect of adeno-associated virus containing miR-15a-5p on the non-perfused area.
[0134] FIG27 : Statistical results of the therapeutic effect of adeno-associated virus containing miR-15a-5p on oxygen-induced retinal neovascularization.
[0135] Figure 28: A: Magnified images of the non-perfused area of the retina show the difference in activation of astrocytes and Müller glia (speckled staining). B: Representative images of retinal tip cells and filopodia are shown. Original magnification, ×40. C: Statistical analysis of retinal filopodia. (n=6 mouse retinas). D: Representative images show the interaction between tip cells, GFAP-positive astrocytes and the end-foot region of Müller cells. Among them, normoxia is the untreated mouse, hyperoxia is the neovascularization model group, the mimic is Agomir, the mimic control is scrambled Agomir, and the VEGF monoclonal antibody is ranibizumab.
[0136] Figure 29: Schematic diagram of the non-perfused area and neovascular area of oxygen-induced retinal neovascularization after treatment with 1 μg of miR-15a-5p mimics. Hyperoxia-normoxia mice serve as the normal mouse neovascularization model group, and hyperoxia-knockout mice serve as the miR-15a-5p knockout mouse neovascularization model group.
[0137] Figure 30: Statistical graph of the non-perfused area of oxygen-induced retinal neovascularization after treatment with 1 μg of miR-15a-5p mimics. Hyperoxia-normoxene mice served as the normal mouse neovascularization model group, and hyperoxia-knockout mice served as the miR-15a-5p knockout mouse neovascularization model group.
[0138] Figure 31: Statistical graph of the neovascular cluster area of oxygen-induced retinal neovascularization treated with 1 μg of miR-15a-5p mimics. Hyperoxia-normoxia mice served as the normal mouse neovascularization model group, and hyperoxia-knockout mice served as the miR-15a-5p knockout mouse neovascularization model group.
[0139] Figure 32: Schematic diagram of the non-perfused area and neovascular area of oxygen-induced retinal neovascularization treated with 1 μg of miR-15a-5p mimic. Hyperoxia-normoxic mice serve as the normal mouse neovascularization model group, while hyperoxia-knockout mice serve as the miR-15a-5p knockout mouse neovascularization model group. The mimic control is scrambled Agomir, and the mimic is Agomir.
[0140] Figure 33: Statistical graph of the non-perfused area in oxygen-induced retinal neovascularization treated with 1 μg of miR-15a-5p mimics. Normal represents the normal mouse neovascularization model group, Knockout represents the miR-15a-5p knockout mouse neovascularization model group, Mimic control represents scrambled Agomir, and Mimic represents Agomir.
[0141] Figure 34: Statistical graph of neovascular cluster area in oxygen-induced retinal neovascularization treated with 1 μg of miR-15a-5p mimics. Normal represents the normal mouse neovascularization model group, Knockout represents the miR-15a-5p knockout mouse neovascularization model group, Mimic control represents scrambled Agomir, and Mimic represents Agomir.
[0142] Figure 35: Magnified images of non-perfused areas of the retina show differences in astrocyte and Müller glial cell activation (speckled staining). Hyperoxia-normoxic mice are the normal mouse neovascularization model group, hyperoxia-knockout mice are the miR-15a-5p knockout mouse neovascularization model group, the mimic control is scrambled Agomir, and the mimic is Agomir.
[0143] Figure 36: Shows representative images of retinal tip cells and filopodia, as well as interactions between tip cells, GFAP-positive astrocytes, and the end-foot regions of Müller cells. Original magnification ×40. Hyperoxic-normoxic mice represent the normal mouse neovascularization model group, hyperoxic-knockout mice represent the miR-15a-5p knockout mouse neovascularization model group, the mimic control represents scrambled Agomir, and the mimic represents Agomir.
[0144] Figure 37: Flowchart of the laser-induced choroidal neovascularization model.
[0145] Figure 38: Fundus fluorescein angiography (FFA) observed the inhibitory effect of miR-15a-5p on choroidal neovascularization.
[0146] Figure 39: Quantitative analysis of leaked fluorescence.
[0147] Figure 40: Choroidal flat mounts were stained with IB4 to quantify the area of neovascular clusters to observe the inhibitory effect of miR-15a-5p on choroidal neovascularization. IB4 positivity indicates neovascular clusters.
[0148] Figure 41: Quantitative analysis results of new blood vessel clusters.
[0149] Figure 42: Schematic diagram of fluorescence of the retina and choroid infected with adeno-associated virus containing miR-15a-5p.
[0150] Figure 43: PCR results show the overexpression of miR-15a-5p in the retina and choroid after adeno-associated virus infection of the retina and choroid. The CNV-AAV-NC group is a control virus group for choroidal neovascularization, and the CNV-AAV-15a group is a miR-15a-5p-containing adeno-associated virus group for choroidal neovascularization.
[0151] Figure 44: Schematic diagram of IB4 staining of choroidal flat mounts to quantify the area of neovascular clusters and observe the inhibition of choroidal neovascularization by adeno-associated virus containing miR-15a-5p.
[0152] Figure 45 shows the statistical results of IB4 staining of choroidal flat mounts to quantify the area of neovascular clusters and observe the inhibition of choroidal neovascularization by adeno-associated virus containing miR-15a-5p.
[0153] Figure 46: H&E staining of the retina shows the interlayer structure and cellular morphology of the retina. The asterisk indicates the outer plexiform layer. GCL stands for ganglion cell layer, IPL for inner plexiform layer, INL for inner nuclear layer, OPL for outer plexiform layer, ONL for outer nuclear layer, and RPE for pigment epithelium. Normoxia represents untreated mice, and hyperoxia represents mice subjected to an oxygen-induced retinal neovascularization model.
[0154] Figure 47: Schematic diagram of quantification of retinal layer thickness using optical coherence tomography (OCT) on postnatal day 42. IPL represents inner plexiform layer, INL represents inner nuclear layer, OPL represents outer plexiform layer, and ONL represents outer nuclear layer. Normoxia represents untreated mice, and hyperoxia represents mice subjected to an oxygen-induced retinal neovascularization model.
[0155] Figure 48: Topographic maps of retinal layer thickness quantified using optical coherence tomography (OCT) on postnatal day 42. Normoxia represents untreated mice, and hyperoxia represents oxygen-induced retinal neovascularization model mice.
[0156] Figure 49: Statistical results of quantification of retinal layer thickness using optical coherence tomography (OCT) on postnatal day 42 in mice, confirming the protective effect of miR-15a-5p on retinal structure. Normoxia represents untreated mice, while hyperoxia represents mice subjected to an oxygen-induced retinal neovascularization model.
[0157] Figure 50: Schematic diagram of retinal function analysis using electroretinal electrophysiology (ERG) on postnatal day 25 and 42. Normoxia represents untreated mice, and hyperoxia represents oxygen-induced retinal neovascularization model mice.
[0158] Figure 51: Statistical results of retinal electrophysiological analysis (ERG) on postnatal day 25 and 42 in mice, confirming the protective effect of miR-15a-5p on retinal function. Normoxia represents untreated mice, while hyperoxia represents mice in an oxygen-induced retinal neovascularization model.
[0159] Figure 52: H&E staining of the retina and choroid showing the interlayer structure and cell morphology of the retina and choroid. GCL stands for ganglion cell layer, IPL stands for inner plexiform layer, INL stands for inner nuclear layer, OPL stands for outer plexiform layer, ONL stands for outer nuclear layer, and RPE stands for pigment epithelium.
[0160] Figure 53: Schematic diagram of analyzing retinal function in a choroidal neovascularization model using retinal electrophysiology (ERG). The mimic control is scrambled Agomir, the mimic is Agomir, and the VEGF monoclonal antibody is ranibizumab.
[0161] Figure 54: Statistical results of retinal function analysis of the choroidal neovascularization model using retinal electrophysiological examination (ERG). The mimic control was scrambled Agomir, the mimic was Agomir, and the VEGF monoclonal antibody was ranibizumab.
[0162] Figure 55: miR-15a-5p inhibits glial cell proliferation in the retina of OIR. (A) Representative images of GFAP immunostaining in retinal sections from normoxic and hyperoxic mice. (B) Quantification and comparison of GFAP intensity across the groups. (C) Western blot showing GFAP expression in the retinas of normoxic and hyperoxic mice. (D) GFAP protein levels were quantified by densitometry, using GAPDH as an internal control.
[0163] Figure 56: Enzyme-linked immunosorbent assay (ELISA) was used to detect the TNFα content in the retinas of mice with oxygen-induced retinopathy at different time points.
[0164] Figure 57: Western Blot showing the expression levels of intercellular adhesion molecule 1 (ICAM-1) in the retinas of mice in each group of oxygen-induced retinopathy.
[0165] Figure 58: Western Blot shows the statistical results of intercellular adhesion molecule 1 (ICAM-1) expression in the retinas of mice in each group of oxygen-induced retinopathy.
[0166] Figure 59: PCR results showing the levels of laser-induced inflammatory factors in the retina of each group of mice. Panel A shows TNFα, Panel B shows ICAM-1, and Panel C shows IL-1β.
[0167] Figure 60: PCR results show that miR-15a-5p can reduce the mRNA level of VEGF in RPE cells induced by TGF-β1.
[0168] Figure 61: Western Blot shows that miR-15a-5p can reduce the increase in VEGF protein level in RPE cells caused by TGF-β1.
[0169] Figure 62: Western Blot shows that miR-15a-5p can reduce the increase in VEGF protein level in RPE cells caused by TGF-β1.
[0170] Figure 63: Elisa showed that miR-15a-5p could reduce the increase in VEGF protein level in RPE cell supernatant caused by TGF-β1.
[0171] Figure 64: Dual-luciferase reporter assay demonstrates that miR-15a-5p can target and bind to VEGF mRNA in vitro. The pmirGLO vector is an empty plasmid, the wild-type contains the VEGF sequence, and the mutant contains a VEGF sequence with different bases in the binding region.
[0172] Figure 65: Intravitreal injection of Agomir-15a-5p mimetic can reverse the hyperoxia-induced increase in VEGF expression levels in the mouse retina.
[0173] FIG66 : Intravitreal injection of Agomir-15a-5p mimetic can reverse the hyperoxia-induced increase in VEGF expression in the mouse retina.
[0174] Figure 67: Intravitreal injection of Agomir-15a-5p mimetic can reverse laser-induced increase in VEGF expression in mouse retina.
[0175] Figure 68: miR-15a-5p mimics inhibit retinal ERK phosphorylation for a longer duration than VEGF monoclonal antibody. Panel A shows a schematic diagram of retinas harvested at P13, P14, P15, P17, P20, and P25 after intravitreal injection on postnatal day 12. Panel B shows increased ERK phosphorylation in the retinas of mice in the hyperoxia group at P12. Panel C shows decreased ERK phosphorylation in the retina of the VEGF monoclonal antibody group at P13. Panel D shows decreased ERK phosphorylation in the retina of the miR-15a-5p mimic and VEGF monoclonal antibody groups at P14. Panel E shows decreased ERK phosphorylation in the retina of the miR-15a-5p mimic group at P15. Panel F shows decreased ERK phosphorylation in the retina of the miR-15a-5p mimic group at P17. Panel G shows no significant difference in ERK phosphorylation between the various retinal groups at P20. Panel H shows no significant differences in ERK phosphorylation signals among the retinas at P25. Panels I, J, K, L, M, N, and O show the statistical results at P12, P13, P14, P15, P17, P20, and P25, respectively. Panel P shows the relative expression of ERK phosphorylation signals in the retinas of each group of mice at different time points.
[0176] Figure 69: PCR results show that miR-15a-5p can reduce the mRNA level of Smad2 in retinal vascular endothelial cells.
[0177] Figure 70: Western Blot results show that miR-15a-5p can reduce the protein level of Smad2 in retinal vascular endothelial cells.
[0178] Figure 71: Western Blot results show that miR-15a-5p can reduce the protein level of Smad2 in retinal vascular endothelial cells.
[0179] Figure 72: Dual luciferase reporter assay shows that miR-15a-5p can target and bind to Smad2 mRNA in vitro, wherein the pmirGLO vector is an empty plasmid, the wild type is a Smad2 base sequence, and the mutant type is a Smad2 base sequence with different bases in the binding region.
[0180] Figure 73: Immunofluorescence staining results of fibrosis markers α-SMA and CD31 in retinal vascular endothelial cells stimulated by TGF-β1 after transfection of miR-15a-5p mimics.
[0181] Figure 74: Immunofluorescence staining results of vimentin in retinal vascular endothelial cells stimulated with TGF-β1 after transfection of miR-15a-5p mimics.
[0182] Figure 75: Western Blot diagram showing changes in fibrosis markers vimentin, α-SMA, and CD31 in retinal vascular endothelial cells stimulated by TGF-β1 after transfection with miR-15a-5p mimics.
[0183] Figure 76: Western Blot statistical results of the changes in fibrosis markers vimentin, α-SMA, and CD31 in retinal vascular endothelial cells stimulated by TGF-β1 after transfection with miR-15a-5p mimics.
[0184] Figure 77: Western Blot diagram of the changes in phosphorylated-Smad2 and total Smad2 in retinal vascular endothelial cells stimulated by TGF-β1 after transfection of miR-15a-5p mimics.
[0185] Figure 78: Western Blot statistical results of the changes in phosphorylated-Smad2 and total Smad2 in retinal vascular endothelial cells stimulated by TGF-β1 after transfection of miR-15a-5p mimics.
[0186] Figure 79: Western Blot results showing the expression levels of fibrosis-related proteins in Müller cells after stimulation with different concentrations of TGF-β2.
[0187] Figure 80: Western Blot results showing the statistical results of the expression levels of fibrosis-related proteins after Müller cells were stimulated with different concentrations of TGF-β2.
[0188] Figure 81: Western Blot results showing the expression levels of fibrosis-related proteins in Müller cells stimulated by TGF-β2 after transfection of miR-15a-5p mimics and mimic control.
[0189] Figure 82: Western Blot results show the statistical results of the expression levels of fibrosis-related proteins in Müller cells after transfection with miR-15a-5p mimics and mimic control, and after stimulation with TGF-β2.
[0190] Figure 83: Immunofluorescence staining results of the cell marker GS in retinal Müller cells stimulated with TGF-β2 after transfection of miR-15a-5p mimics.
[0191] Figure 84: Immunofluorescence staining results of fibrosis marker α-SMA and activation marker GFAP in retinal Müller cells after transfection with miR-15a-5p mimics and stimulation with TGF-β2.
[0192] Figure 85: PCR results show the expression level of TNF-α in Müller cells after transfection with miR-15a-5p mimics and mimic control and stimulation with TGF-β2.
[0193] FIG86 : PCR results show the expression level of MCP-1 in Müller cells after transfection with miR-15a-5p mimics and mimic control and stimulation with TGF-β2.
[0194] Figure 87: Western Blot results showing the total protein and phosphorylation levels of Smad2 in Müller cells following TGF-β2 stimulation after transfection with miR-15a-5p mimics and mimic control. P-Smad2 represents phosphorylated Smad2, and T-Smad2 represents total Smad2.
[0195] Figure 88: Western Blot results showing the statistical results of total Smad2 protein and phosphorylation levels in Müller cells transfected with miR-15a-5p mimics and mimic control, and stimulated with TGF-β2. P-Smad2 represents phosphorylated Smad2, and T-Smad2 represents total Smad2.
[0196] Figure 89: Retinal cryosections of each group of hyperoxia-induced mice show the expression and localization of α-SMA and retinal blood vessels.
[0197] Figure 90: Retinal cryosections of each group of mice induced by hyperoxia show the expression and localization of fibronectin and retinal blood vessels.
[0198] Figure 91: Retinal cryosections from each group of mice induced by hyperoxia show the expression and localization of α-SMA and activated Müller cells in the retina. GFAP indicates activated Müller cells.
[0199] Figure 92: Western blot analysis shows the expression of retinal fibronectin proteins. Figure A shows the expression of fibronectin in the retinas of mice induced by hyperoxia. Figure B shows the statistical results of fibronectin expression levels. Figure C shows the expression of TGFβ receptor 2 and α-SMA proteins in the retinas of mice induced by hyperoxia. Figure D shows the statistical results of TGFβ receptor 2 and α-SMA protein expression levels. Figure E shows the expression of phosphorylated Smad2 and total Smad2 in the retinas of mice induced by hyperoxia. Figure F shows the statistical results of phosphorylated Smad2 and total Smad2 expression levels in the retinas of mice induced by hyperoxia.
[0200] Figure 93: Safety assessment of intraocular administration of miR-15a-5p on oxygen-induced development in mice. Figure A shows the weight changes of mice from the day of administration (P12) to P42 (P42), when the mice reach near adulthood. Figure B shows the plasma color of each group. Figure C shows the serum creatinine level of mice. Figure D shows the serum urea level of mice. Figure E shows the plasma triglyceride level of mice. Figure F shows the plasma total cholesterol level of mice. Figures G and H show H&E staining of the liver and kidney structures of mice at 17 days (P17), 25 days (P25), and 42 days (P42) after birth.
[0201] Figure 94: Safety assessment of intraocular administration of miR-15a-5p on normal mouse development and retina. Figure A shows changes in mouse body weight from the day of administration (P12) to P42 (P42), when mice reach near adulthood. Figure B shows serum creatinine levels. Figure C shows serum urea levels. Figure D shows plasma triglyceride levels. Figure E shows plasma total cholesterol levels. Figure F shows fluorescent sections of the liver and kidney at different time points after administration. Figures G and H show H&E staining of liver and kidney structures at P17, P25, and P42. Figures I, J, and K show OCT results demonstrating the effects of intravitreal injection of a miR-15a-5p mimic, a mimic control, and a VEGF monoclonal antibody on retinal thickness. Figures L and M show frozen sections of the retina demonstrating activation of retinal Müller cells following intravitreal injection of a miR-15a-5p mimic, a mimic control, and a VEGF monoclonal antibody.
[0202] Figure 95: Intravitreal injection of miR-15a-5p mimics demonstrated therapeutic effects on retinal photoreceptor and bipolar cell damage in diabetic mice (leptin receptor-deficient model). The a-wave represents the response of photoreceptors to light stimulation, the b-wave represents the response of bipolar cells to light stimulation, and the op-wave is a set of oscillatory potentials within the b-wave, generally believed to represent the response of bipolar cells and amacrine cells to light stimulation.
[0203] Figure 96 shows the statistical results of the therapeutic effect of intravitreal injection of miR-15a-5p mimics on retinal photoreceptor damage in diabetic mice (leptin receptor-deficient model mice). The b wave represents the response of photoreceptor cells to light stimulation.
[0204] Figure 97 shows the statistical results of the therapeutic effect of intravitreal injection of miR-15a-5p mimics on retinal bipolar cell damage in diabetic mice (leptin receptor-deficient model mice). The a wave represents the response of bipolar cells to light stimulation.
[0205] Figure 98: Statistical results of the therapeutic effect of intravitreal injection of miR-15a-5p mimics on retinal bipolar cell damage in diabetic mice (leptin receptor deficient model mice). The op wave is a group of oscillatory potentials in the b wave, which is generally believed to represent the response of bipolar cells and amacrine cells to light stimulation.
[0206] Figure 99: Differences in the growth of superficial retinal vascular plexuses along astrocyte templates between normal and knockout mice at P7. Panel A shows representative images of superficial retinal vessels stained with IB4. Magnifications from left to right are 5X, 10X, and 20X. Panel B shows the statistical results of the area of retina covered by superficial vessels. Panel C shows the statistical results of the number of nodes generated by superficial vessel intersections. Panel D shows the statistical results of the total length of superficial vessels. Panel E shows the statistical results of the total branch length of superficial vessels. Panel F shows representative images of superficial retinal vessels stained with IB4 and GFAP. Panel G shows the statistical results of the number of nodes generated by superficial vessel intersections in GFAP-positive areas. Panel H shows the statistical results of the total lumen length in GFAP-positive areas. Panel I shows the statistical results of the degree of overlap between superficial vessels and GFAP-positive areas.
[0207] Figure 100: Differences in the growth of the superficial and deep retinal vascular plexuses between normal and knockout mice at P9. A shows a representative image of superficial retinal vessels stained with IB4. Magnifications from left to right are 5X, 10X, and 20X. B shows a representative image of deep retinal vessels covering the retina stained with IB4. C shows the statistical results of the number of nodes generated by the interlacing of superficial vessels. D shows the statistical results of the number of superficial vascular meshes. E shows the statistical results of the total length of superficial vessels. F shows the statistical results of the total branch length of superficial vessels. G shows the statistical results of the area covered by the applied vessels.
[0208] Figure 101: Therapeutic effect of miR-15a-5p mutant on retinal neovascularization. DETAILED DESCRIPTION
[0209] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, not all. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making any creative efforts shall fall within the scope of protection of the present invention.
[0210] The experimental methods involved in the embodiment are as follows:
[0211] 1. Effects of miR-15a-5p on human retinal endothelial cells
[0212] 1.1 Cell culture
[0213] Human retinal microvascular endothelial cells (HRMECs) were purchased from angiopromie and cultured in endothelial cell culture medium (ECM) supplemented with 5% fetal calf serum, 1% penicillin-streptomycin, and endothelial cell growth supplement (ECGS). The cells were incubated at 37°C in 5% carbon dioxide. The culture medium was changed every two days. Experiments were performed on cells from passages 3 to 6.
[0214] 1.2 CCK-8 assay for cell proliferation
[0215] Using the Cell Counting Kit (CCK-8) CCK-8 / WST-8: Cells were digested and prepared into a single-cell suspension. Cells were seeded at a density of 2,000 cells / well in a 96-well plate, with five replicates per well. After cells adhered, the medium was changed and the target culture medium was added. Cell viability was then measured 24 hours later. Prior to the assay, 10 μl of CCK-8 reagent was added to each well and incubated at 37°C in the dark for 2 hours. The incubated culture medium was then transferred to a microplate reader, and absorbance was measured at 450 nm using a BIO-RAD microplate reader.
[0216] 1.3 Cell transfection
[0217] HRMECs were seeded at a density of 2,000 cells / well in a 96-well plate and cultured overnight in a cell culture incubator. 5 μl of Opti-MEM medium was added to each of two EP tubes. 0.15 μl of Lipofectamine 3000 reagent was added to the first tube, and 0.15 μl of the mock control / mock / inhibitor control / inhibitor was added to the second tube. The two tubes of liquid were mixed and incubated at room temperature for 5 minutes. After that, 10 μl of the mixture was added to one well. When preparing the solution, it is generally necessary to calculate the total amount of liquid added to all wells, mix it, and add it to each well one by one, rather than preparing the solution separately for each well to avoid errors. Other mock controls, inhibitor controls, and inhibitors were also transfected into cells using the same method, but the inhibitor control and inhibitor needed to be added in twice the amount of the mock.
[0218] 1.4 Extraction of total cell RNA
[0219] Add 500 μl of Trizol to the cells, pipette and let stand at room temperature for 5 minutes, add 100 μl of buffer A, shake vigorously for 15 seconds, and let stand at room temperature for 3 minutes. After stratification, centrifuge at 15,000 g at 4°C for 5 minutes. Pipette 200 μl of the upper aqueous phase into another 1.5 ml EP tube, add 1.5 times the volume of anhydrous ethanol, turn it upside down, add it to the RNA adsorption column provided by the kit (EZB, product number EZB-RN5), centrifuge at 4,000 g for 1 minute, remove it and discard the liquid in the collection tube, add 500 μl of wash buffer 1 liquid to the centrifuge column, and then centrifuge at 12,000 g for 1 minute. Centrifuge until all the liquid has passed through the centrifuge column. Then add 500μl of wash buffer 2 to the centrifuge column, centrifuge at 12000g for 1 min, take out and pour out the liquid in the collection tube, centrifuge at 12000g for 1 min, take out and pour out the liquid in the collection tube, change the adsorption column to a new 1.5ml EP tube, open the lid and let it air for 2 minutes, add 20μl DEPC water, centrifuge at 12000g for 1 minute, add the centrifuge liquid to the adsorption column, incubate at room temperature for 5 minutes, and centrifuge at 12000g for 1 minute. The liquid in the collection tube is total RNA, and the concentration is measured using Nano Drop.
[0220] 1.5 Reverse transcription
[0221] Add the following reagents to a 200 μl EP tube. The volume of RNA will vary depending on the RNA concentration, so a total of 500 ng of RNA should be used. Then, add 1 μl of gDNA remover, mix well, and incubate at room temperature for 5 minutes. Add the following reagents according to Table 1. Place the tube in a PCR instrument and set the following program: heat at 37°C for 15 minutes, then at 42°C for 10 minutes, and then at 95°C for 3 minutes. Immediately place the resulting cDNA on ice.
[0222] Table 1
[0223] 1.6qRT-PCR
[0224] Prepare the reaction liquid in each well according to the proportions in Table 2, mix SYBR Green Master with cDNA, mix upstream and downstream primers with water, make up for the insufficient cDNA with RNeasy free water, mix well and add to the 384-well plate. Be careful to avoid light. After the sample is added, stick the sealing film on the plate, centrifuge at 4℃2000rpm for 3 minutes, and then put it on the machine. The program is set as: the first step is 95℃15min, the second step is 94℃15s-55℃30s-70℃30s and cycle 40 times, the third step is 95℃15s-55℃15s-95℃15s. U6 is used as the internal reference for sEVs, and cel-miR-39 is used as the external reference for plasma and vitreous. The expression level of miRNA is measured with 2 ∧-Δct The primer sequences of each miRNA are shown in Table 3.
[0225] Table 2
[0226] Table 3
[0227] 1.7 Cell scratch assay
[0228] HRMECs were digested and seeded onto 6-well plates. When cell confluency reached 75%-80%, the cells were transfected with a mock control, a mock, an inhibitor control, and an inhibitor, respectively. Six hours later, the medium containing the transfection reagent was aspirated, and a line was scratched across the center of each well using a 1ml pipette tip with uniform force. The cells were then washed twice with PBS buffer to remove detached cells. The cells were photographed under a microscope and stored, noting the location of the photo to ensure that the same spot was retained for subsequent photos. The images were then photographed again 24 hours later and stored. The images were analyzed using Image J software to calculate the scratch area.
[0229] 1.8 Transwell cell migration assay
[0230] A Transwell cell migration assay was used to examine the effect of miR-15a-5p transfection on cell migration. After pretreatment, HRMECs were trypsinized, and 8,000 cells were seeded into the upper chamber of the wells. After 24 hours of culture, the cells were washed three times with PBS. The cells were then fixed with PFA and stained with 0.01% crystal violet buffer. Five randomly selected fields of view were counted under a microscope.
[0231] 1.9 Endothelial cell tube formation assay
[0232] Matrigel (Corning, Cat. No. 354234) was thawed at 4°C for 12 hours and applied to the surface of a 48-well cell plate to support tube formation. The plate was then cured at 37°C for 40 minutes. After pretreatment, HRMECs were seeded into the Matrigel-coated 48-well plate. Three hours later, five fields from each well were imaged using an inverted phase microscope. Image-J software was used to calculate the total length of the vascular lumen and the number of nodes.
[0233] 1.10 Immunofluorescence cell staining
[0234] After pretreatment, HRMECs were fixed in 4% paraformaldehyde for 15 minutes and then soaked in PBS with 0.1% Triton-X100 (PBST) for 15 minutes. After blocking with 5% bovine serum albumin (BSA) at room temperature, the cells were incubated with primary antibodies against vimentin (1:300, Abcam, ab45939), α-SMA (1:500, Abcam, ab124964), and CD31 (1:150, Abcam, ab24590) at 4°C overnight. The cells were washed three times with PBST. The cells were then incubated with Alexa fluor 488-conjugated goat anti-rabbit IgG H&L (1:1000, Abcam) for vimentin or with Alexa fluor-647-conjugated goat anti-mouse IgG H&L (1:1000, Abcam) at room temperature. The cell nuclei were labeled with 4,6-diamino-2-phenylindole (1:500, Solarbio). The cells were observed and photographed under a confocal laser scanning microscope (LSM800, Zeiss, Germany).
[0235] 2. Screening and Verification of miR-15a-5p Target Genes
[0236] Target gene prediction
[0237] The target genes of the screened differential miRNAs were predicted in three databases: TargetScan, PITA, and microRNAorg.
[0238] 2.2 Dual luciferase reporter gene assay
[0239] A luciferase reporter gene assay was used to verify whether Smad2 is a target gene of miR-15a-5p. Dual luciferase reporter plasmid: pmIRGLO-Smad2 wild type and pmIRGLO-Smad2 mutant were constructed, and the empty plasmid was used as a control plasmid. The reporter plasmid was co-transfected into HEK-293 cells with miR-15a-5p mimics or scrambled control. 48 hours after transfection, the cells were lysed and the supernatant was collected according to the steps of the dual luciferase reporter assay system (Gene Pharma, Cat. No. G06001). TECAN Infinite 200 (Germany) was used to detect the activity of firefly luciferase reporter gene and Renilla luciferase reporter gene. The ratio of firefly luciferase was expressed as relative luciferase activity to Renilla luciferase. Each experiment was repeated 3 times. The process of verifying whether VEGF is a target gene of miR-15a-5p was the same as above.
[0240] 3. Animal Experimental Procedures
[0241] 3.1 Establishment of mouse OIR model
[0242] C57BL / 6J mice were used to establish a model of oxygen-induced neovascular retinopathy. Newborn and lactating female mice were exposed to 75% oxygen from postnatal day 7 (P7) to postnatal day 12 (P12). On postnatal day 12, the mice were removed from the oxygen chamber and placed in normoxia. Because hypoxia induces neovascularization, retinal neovascularization peaks on postnatal day 17 (P17). This is accompanied by retinal inflammation, neural damage, and fibrotic changes.
[0243] 3.2 Intravitreal injection of mice
[0244] On day 12, 1 μg of modified miR-15a-5p mimic (Agomir) was injected into the vitreous cavity of mice using a 34-gauge needle (Hamilton, Reno, NV, United States). The same number of mice were injected with scrambled Agomir as a negative control group. Alternatively, 1 μl of adeno-associated virus (AAV) was injected into the vitreous cavity of mice at a titer of 1 × 10 12 After the injection, antibiotic gel is applied to cover the ocular surface to prevent corneal edema.
[0245] 3.3 Differential uptake of modified and unmodified miR-15a-5p by mouse retina
[0246] Six-week-old male C57BL / 6J mice were used in this experiment. After anesthesia, unmodified miR-15a-5p mimics (mimics) or modified miR-15a-5p mimics (Agomir) at a concentration of 1 μg (Genepharma) were injected into the vitreous cavity using a 34-gauge needle (Hamilton, Reno, NV, United States). An equal number of mice were injected with PBS as a negative control group. Retinas were harvested 8 hours, 24 hours, 48 hours, 5 days, and 7 days after injection for measurement of miR-15a-5p levels.
[0247] 3.4 Retinal flat mount
[0248] Mice were killed at P17 and their eyeballs were removed. The retinas were peeled off, fixed with 4% paraformaldehyde, and cut into four radial flaps. Goat serum was used for blocking for 2 hours, and retinal blood vessels were stained using IB4 (Thermo, Catalog No. I21411) or anti-glial fibrillary acidic protein (GFAP) antibody (Abcam, Catalog No. ab7260). After washing for 5 hours, goat anti-rabbit IgG (Abcam 150077) was used as a secondary antibody for staining, and anti-fluorescence attenuation mounting medium was used for mounting after washing for 5 hours. Retinal blood vessel images were taken using a confocal laser scanning microscope (LSM800, Zeiss, Germany). Quantitative analysis of new blood vessels and non-perfused areas was performed using Photoshop.
[0249] 3.5 Tissue immunofluorescence staining.
[0250] Eyeballs were dissected and quickly frozen in embedding gel. Retinal sections (8 μm) were sectioned and fixed in 4% paraformaldehyde for 20 minutes at room temperature. Sections were then incubated overnight at 4°C with antibodies against GFAP, α-SMA (Abcam, Catalog No. ab1224964), Fibronectin (Abcam, Catalog No. ab45688), and IB4 (Thermo, Catalog No. I21411). After washing three times with PBS, retinal sections were incubated with Alexa Fluor 488-conjugated IgG (Abcam, Catalog No. ab150077) for 2 hours. After washing three times with PBS, cell nuclei were labeled with 4,6-diamino-2-phenylindole (1:500, Solarbio). After washing three times with PBS, anti-fluorescence decay mounting medium was applied and the sections were sealed with coverslips. Images were then photographed using a confocal laser scanning microscope (LSM800, Zeiss, Germany).
[0251] 3.6 TUNEL analysis
[0252] TUNEL assay was performed on retinal cryosections using the TUNEL system (Roche, cat. no. 11684795910) according to the manufacturer's instructions.
[0253] 3.7 Western blot analysis
[0254] After BCA quantification, take an equal amount of protein sample, add PBS to a volume of 20 μl, add 5 μl of protein loading buffer (5×), and heat at 95°C for 5 minutes. Protein electrophoresis conditions are 100V for 90 minutes. Electrotransfer conditions are 100V for 100 minutes. Remove the PVDF membrane after electrophoresis, block it, and incubate it with the primary antibody overnight. Discard the primary antibody and wash it three times. Add the secondary antibody and incubate it on a shaker at room temperature for 2 hours. Discard the secondary antibody, add TBST, and wash it three times for 10 minutes each. Use ECL supersensitive luminescence solution for development.
[0255] 3.8 Histopathology and Immunohistochemistry
[0256] Eyes were removed from mice sacrificed by cervical dislocation at P17, and kidneys and livers were removed and fixed at P25 and P42. Specimens were stained with hematoxylin and eosin (H&E) and imaged using a light microscope.
[0257] 3.9 Electroretinogram (ERG)
[0258] Mice were dark-adapted for 18 hours and operated according to the manufacturer's instructions (Phoenix Micron VI) with white light flashes ranging from 0.01 to 1 cd-s / m. A notch filter was used to reduce signal noise at 60 Hz; a low-cut filter was set to 0.3 Hz; and a high-cut filter was set to 500 Hz. A- and b-wave amplitudes were measured. Mice were anesthetized using a heating pad, and the eyes were moistened with a drop of balanced saline solution as needed.
[0259] 3.10 OCT
[0260] The German Heidelberg SPECTRALIS-OCT was used to observe changes in the fundus structure of mice. Tropicamide eye drops were used to dilate both eyes. After the mice reached a stable anesthesia phase, sodium hyaluronate gel was applied to the eyes and a retinal scan was performed. The scan image was centered on the mouse's optic disc and captured the full thickness of the retina.
[0261] 3.11 Establishment of a laser-induced mouse choroidal neovascularization model
[0262] Six-week-old male C57BL / 6J mice were used in this experiment. After anesthesia, the pupils were dilated and a Phoenix laser was used to irradiate the retina, destroying the retinal pigment epithelium and choroid. Seven days later, new blood vessels emerged from the choroid and invaded the retina.
[0263] 3.12 Subretinal injection of drugs in mice
[0264] Six-week-old male C57BL / 6J mice were used for this experiment. After anesthesia, the pupils were dilated and a 34-gauge needle (Hamilton, Reno, NV, United States) was inserted through the limbus of the cornea and sclera. The retina was lifted and 1 μl of adeno-associated virus (AAV) was injected into the subretina of the mice at a titer of 1 × 10 12 After the injection, antibiotic gel is applied to cover the ocular surface to prevent corneal edema.
[0265] 3.13 Fundus photography and fundus fluorescein angiography
[0266] Laser-induced neovascularization model mice were anesthetized, their pupils dilated, and photographed using a Phoenix fundus lens focused on the center of the optic disc using a transparent gel. Subsequently, 10% sodium fluorescein (5 mL / kg) was injected intraperitoneally. Ten minutes later, fundus photography was performed under a darkfield filter to reveal leakage spots.
[0267] 3.14 Choroidal neovascularization quantification
[0268] Seven days after model formation, OIR mice were killed by cervical dislocation and their eyeballs were removed. The choroid was peeled off, fixed with 4% paraformaldehyde, and cut into four radial flaps. Goat serum was used for blocking for 2 hours, and choroidal blood vessels were stained using IB4 (Thermo, product number I21411). After washing for 5 hours, the slides were mounted with anti-fluorescence attenuation mounting medium. Choroidal blood vessel images were captured using a confocal laser scanning microscope (LSM800, Zeiss, Germany). Quantitative analysis of new blood vessels was performed using Photoshop.
[0269] 4. Safety Assessment of Intraocular Injection of miR-15a-5p on Mouse Development
[0270] 4.1 Collection of blood samples
[0271] Blood samples were collected from behind the eyeball, centrifuged at 2000 g for 15 minutes, serum was separated, and then stored at -80°C. The liver, spleen, brain, and kidneys were dissected out.
[0272] 4.2 Histopathological examination
[0273] The main organ samples (liver, spleen, kidney) were fixed with 4% neutral buffered paraformaldehyde for 24 hours, embedded in paraffin, cut at 3 μm and stained with hematoxylin and eosin. Micrographs were taken using an Olympus BX51 microscope and an Olympus DP71CCD camera (Olympus Corporation, Tokyo, Japan).
[0274] 4.3 Determination of serum biochemical parameters
[0275] Serum concentrations of creatinine (Elabscience, Cat. No. EBCK188M), urea nitrogen (Elabscience, Cat. No. EBCK183M), triglycerides (Elabscience, Cat. No. EBCK126M), and total cholesterol (Elabscience, Cat. No. EBCK109S) were measured using commercially available test kits. The concentration of each parameter was calculated according to the manufacturer's instructions.
[0276] In addition, the sources of reagents used in the text are:
[0277] Mimics (miR-15a-5p mimics) were purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd., catalog number B02001;
[0278] Agomir (Agomir-15a-5p mimetic) was purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd., catalog number B06001; the structure is: the sense chain is SEQ ID NO: 1, the antisense chain is SEQ ID NO: 6, and then modified with two thiolate backbones at the 5' end, four thiolate backbones at the 3' end, cholesterol at the 3' end, and methoxyl modifications throughout the chain.
[0279] Inhibitor (miR-15a-5p inhibitor) was purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd., catalog number B03001;
[0280] Smad2-WT vector was purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd., catalog number C09005-36176;
[0281] The Smad2-mut vector was purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd., catalog number C09006-36176.
[0282] VEGF-WT vector was purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd., catalog number C09005-56969;
[0283] VEGF-mut vector was purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd., catalog number C09006-56969.
[0284] Adeno-associated virus was purchased from Shanghai Jima Pharmaceutical Technology Co., Ltd., catalog number D08001.
[0285] Example 1: Transfection of miR-15a-5p mimics or inhibitors into retinal endothelial cells can increase and decrease the expression level of miR-15a-5p, respectively
[0286] MiRNA mimics and inhibitors can simulate its biological effects in vitro. The miR-15a-5p mimic is the base sequence of miR-15a-5p synthesized in vitro, and the miR-15a-5p inhibitor is the base complementary sequence of miR-15a-5p synthesized in vitro.
[0287] Mimics of miR-15a-5p:
[0288] Sense strand: UAGCAGCACAUAAUGGUUUGUG (SEQ ID NO: 1);
[0289] Antisense strand: CACAAACCAUUAUGUGCUGCUA (SEQ ID NO: 6).
[0290] First, we needed to confirm that transfection of miR-15a-5p mimics or inhibitors using lipofectamine 3000 could indeed increase or decrease miR-15a-5p expression in cells. qRT-PCR results showed that compared with the mimic control group (scrambled mimic), transfection of miR-15a-5p mimics increased intracellular miR-15a-5p levels by approximately 150-fold (Figure 1), with a statistically significant difference (P < 0.05). Compared with the inhibitor control group (scrambled inhibitor), transfection of cells with the miR-15a-5p inhibitor decreased intracellular miR-15a-5p levels by 80% (Figure 1), a statistically significant difference (P < 0.05).
[0291] The retina and choroid contain numerous blood vessels, among which endothelial cells are crucial for maintaining vascular permeability. Therefore, retinal endothelial cells (HRMECs) are a representative sample for this experiment. Example 1 demonstrates that transfection of miR-15a-5p mimics and inhibitors into HRMECs in vitro can either overexpress or downexpress miR-15a-5p, providing a foundation for subsequent observations of miR-15a-5p's effects on cells.
[0292] Example 2: Optimal concentration of VEGF to stimulate pathological proliferation of retinal vascular endothelial cells
[0293] VEGF is a known potent factor that induces angiogenesis in vitro and in vivo, and has a strong pathogenic effect in retinopathy of prematurity, diabetic retinopathy, and choroidal neovascularization. In in vitro experiments, VEGF can establish a model of pathological proliferation in HRMECs. Therefore, it is necessary to determine the concentration of VEGF stimulation. VEGF at concentrations of 0, 10, and 20 ng / mL was selected to stimulate HRMECs. CCK-8 assay results showed that concentrations above 10 ng / mL could induce significant proliferation of HRMECs (Figure 2). At the same time, this concentration did not cause changes in miR-15a-5p expression in HRMECs (Figure 3).
[0294] Example 3: The therapeutic effect of miR-15a-5p on pathological proliferation of retinal vascular endothelial cells in vitro
[0295] After confirming that 10 ng / mL VEGF induced pathological proliferation of HRMECs without altering miR-15a-5p expression, we further investigated the effects of miR-15a-5p on HRMECs under both physiological and pathological conditions (10 ng / mL VEGF). The CCK-8 assay, a commonly used method for measuring cell proliferation and division activity, showed that miR-15a-5p mimics could reduce VEGF-induced abnormal cell proliferation (Figure 4). A wound wound healing assay demonstrated that miR-15a-5p mimics attenuated VEGF-induced cell proliferation (Figures 5-6). A Transwell assay, designed to assess cell migration, demonstrated that miR-15a-5p mimics attenuated VEGF-induced abnormal cell migration (Figures 7-8). A tube formation assay simulates the ability of cells to form tubes in vitro, demonstrating that miR-15a-5p mimics attenuated VEGF-induced tube formation (Figures 9-11). All of these differences were statistically significant (P < 0.05).
[0296] VEGF can induce endothelial cell proliferation in vivo, further inducing the development of new blood vessels. Unlike physiological blood vessels, these new vessels lack tight junctions, allowing their contents to leak through the walls into the retina and vitreous, causing fundus exudates and hemorrhages, significantly impairing normal visual function. Transfection of HRMECs with a miR-15a-5p mimic in vitro reduced VEGF-induced abnormal cell proliferation, migration, and tube formation. This suggests that the miR-15a-5p mimic has a significant therapeutic effect on the pathological proliferation of HRMECs in vitro.
[0297] Example 4: Mouse retina absorbs modified miR-15a-5p mimics better
[0298] Common miRNA mimics are mimics, which are composed of unmodified bases and are well absorbed by cells in vitro. In in vivo experiments, unmodified bases are easily degraded by ubiquitous nucleases in the body. Therefore, this example uses modified miRNA, such as those modified by adding cholesterol. To compare the absorption effect of the modified and unmodified mimics by the retina, this example compares the efficiency of mice absorbing the same amount of miR-15a-5p mimics at different times. Among them, the modified mimic is Agomir. The results are shown in Figure 12. 24 hours after the injection of the mimic, a significant difference was observed. Agomir has good tissue compatibility, and the retina's absorption effect on Agomir is 2.5 times that of the mimic, and the high level persists until the 7th day after injection. Therefore, in subsequent animal experiments, Agomir (Agomir-15a-5p) was selected as the mimic of miR-15a-5p for in vivo injection.
[0299] Example 5: Therapeutic effect of miR-15a-5p on hyperoxia-induced retinal neovascularization in mice
[0300] To investigate the effects of miR-15a-5p on neovascularization, we selected an oxygen-induced retinopathy (OIR) model. The model construction flowchart is shown in Figure 13. This model is the most commonly used retinal neovascularization model, simulating the pathological process of retinal neovascularization (RNV). During this process, miR-15a-5p expression levels in the retina were measured at selected time points during development. As shown in Figure 14, miR-15a-5p expression levels increased significantly at postnatal days 14 and 17, the peak of neovascularization. To further explore the effects of miR-15a-5p on neovascularization in vivo, we first established a concentration gradient of an Agomir-15a-5p mimic. Different doses of the mimic and a mimic control were injected on postnatal day 12. Retinal neovascularization was analyzed by IB4 staining on postnatal day 17. The results showed that the inhibitory effect of Agomir-15a-5p on neovascularization was dose-dependent ( Figures 15-16 ), and 0.5 μg-1.5 μg of Agomir-15a-5p mimetic could significantly inhibit retinal neovascularization ( Figures 15-16 ).
[0301] At the same time, VEGF monoclonal antibody was selected as a positive control. The results showed that 2 μg of VEGF monoclonal antibody had the best inhibitory effect on retinal blood vessels. Subsequently, 2 μg was selected as the therapeutic concentration for further verification (Figure 17). In order to observe the distribution and duration of agomir in the retina after intravitreal injection, CY3-labeled agomir-15a-5p was injected into the vitreous body of mice. It was diffusely distributed in the retina 8 hours after injection, and the fluorescence intensity reached a peak value 24 hours after injection (A, B in Figure 18). In addition, the polymerase chain reaction was used to detect the increase in agomir in the retina. Agomir-15a-5p increased by about 2-3 times 24 hours after injection, reached a peak concentration of about 3-5 times 48 hours after injection, and its high expression lasted for 5 days (C in Figure 18).
[0302] Subsequently, 1 μg was selected as the therapeutic concentration for further validation, and a VEGF monoclonal antibody was used as a positive control. The results showed that the Agomir-15a-5p mimetic could reduce retinal neovascularization to 65% of the control group (Figures 19-20). Compared with the VEGF monoclonal antibody, the Agomir-15a-5p mimetic also promoted the recovery of retinal non-perfused areas, reducing the area of retinal non-perfused areas to 73% of the control group (Figures 19 and 21).
[0303] Adeno-associated virus (AAV) is a highly efficient gene delivery tool that can infect retinal cells, causing them to overexpress miR-15a-5p. The AAV carries the nucleic acid sequence TAGCAGCACATAATGGTTTGTG (SEQ ID NO: 9), which can be transcribed into miR-15a-5p in vivo to exert its therapeutic effects.
[0304] On the fifth day after birth, the mice were injected intraperitoneally with adeno-associated virus (1×10 12 ) and control virus (1×10 12). The structure of the virus is shown in Figure 22. On the 12th day, the retina was harvested and the site of infection by the adeno-associated virus was observed through frozen sections of the eyeball. The results in Figure 23 show that the adeno-associated virus containing miR-15a-5p infected the retina, and the retina showed diffuse fluorescence. Subsequently, the miR-15a-5p content in the retina of each group was detected by PCR. The results are shown in Figure 24. The miR-15a-5p in the retina of the group injected with the adeno-associated virus containing miR-15a-5p was 13 times that of the control group, indicating that the virus can successfully overexpress miR-15a-5p. The retinal neovascularization of oxygen-induced mice was quantified on the 17th day after birth. The results showed that the retinal neovascularization and non-perfused areas in the group injected with the adeno-associated virus containing miR-15a-5p were significantly reduced (Figures 25-27). The above results indicate that adeno-associated virus containing miR-15a-5p can successfully deliver miR-15a-5p into mouse retinal cells, and has a therapeutic effect on hyperoxia-induced retinal neovascularization in mice and can promote the recovery of non-perfused areas.
[0305] Example 5 uses two methods to deliver miR-15a-5p, one is modified miR-15a-5p and the other is adeno-associated virus. The purpose of increasing the content of miR-15a-5p in the retina was achieved by injecting two substances into the vitreous cavity. The oxygen-induced retinopathy model adopted is a classic fundus disease model that can simulate the neovascular phenotype of various fundus diseases, such as diabetic retinopathy and retinopathy of prematurity. This example observed the therapeutic effect of miR-15a-5p on the neovascularization and non-perfused areas of the model, and found that miR-15a-5p has a therapeutic effect on retinal neovascularization and can promote the recovery of non-perfused areas.
[0306] Example 6: miR-15a-5p promotes the recovery of hyperoxia-induced retinal nonperfusion areas in mice
[0307] The attachment of endothelial apical cells and astrocytes is crucial for vascular remodeling in non-perfused areas. To explain the role of miR-15a-5p in promoting vascular reconstruction in non-perfused areas, we observed the relationship between astrocytes and vascular sprouts in the retina of mice on day 17. Astrocytes in the retinal vascular occlusion area of OIR mice degenerated, and the loss of astrocytes was accompanied by increased GFAP reactivity of Müller cells, which was manifested as spotted staining at the ends of Müller cells in the superficial vascular plexus (Figure 28A, second column). Specifically, the last row of Figure 28A shows that retinal astrocytes in the normoxia group exhibited astrocyte-stretched morphology, while the hyperoxia control treatment group lacked stretched astrocyte morphology. Instead, there was a spotted irregular cell morphology, which is the footplate of activated Müller cells, representing an increased inflammatory reactivity of Müller cells. However, compared with the retinas of the OIR untreated group, after Agomir treatment, astrocytes in the non-perfused areas of the mouse retina formed better networks and retained their normal star / dendrite morphology and density (Figure 28A third column). Figure 28B shows the filopodia emitted by the endothelium at the edge of the non-perfused area, indicating the reconstruction of degenerated blood vessels. Our experiments showed that compared with the OIR control group, after Agomir treatment, the filopodia emitted by the endothelial tip cells near the non-perfused area increased by 5 times (Figure 28C), and the astrocytes in the non-perfused area provided a scaffold and template for the filopodia to extend from the tip endothelial cells into the occluded retina (Figure 28D). Specifically, in the second row of Figure 28D, the blood vessels in the normoxia group had no gaps to cling to the astrocytes, while the blood vessels in the hyperoxia untreated group had nowhere to cling to and grow, but instead had many spotted cells. After Agomir treatment, the blood vessels clinging to the astrocytes were restored, which ultimately promoted the recovery of the non-perfused area. VEGF monoclonal antibodies had no effect on the above-mentioned vascular and astrocyte attachment relationship. Therefore, miR-15a-5p-mediated vascular rescue in the non-perfused retina is related to the protection of endogenous astrocytes in the vascular occlusion area.
[0308] Example 7: Effects of miR-15a-5p deficiency on hyperoxia-induced retinal neovascularization and non-perfused areas in mice
[0309] The inhibitory effect of miR-15a-5p on neovascularization was verified in miR-15a-5p knockout mice. The oxygen-induced retinopathy (OIR) model was selected to further verify the role of miR-15a-5p in retinal angiogenesis. Normal mice and knockout mice were placed in a hyperoxia environment to induce pathological retinal neovascularization (Figure 29). Retinal neovascular clusters and vascular occlusion areas were analyzed by IB4 staining on day 17 after birth. The results showed that miR-15a-5p deficiency significantly increased the non-perfused area and neovascular area of the OIR retina (Figures 30-31). This indicates that the loss of miR-15a-5p affects the formation of blood vessels in the mouse OIR model. Next, we studied the effects of a miR-15a-5p mimic (Agomir-15a-5p) on the oxygen-induced neovascularization model in normal mice and knockout mice to further determine whether miR-15a-5p regulates abnormal retinal angiogenesis (Figure 32). The results showed that intravitreal injection of Agomir-15a-5p not only reduced the non-perfused area and neovascularization area of the retina in normal mice, but also reversed the increase in non-perfused area and pathological neovascularization area of the retina caused by miR-15a-5p deficiency in knockout mice (Figures 32-34).
[0310] We then examined the relationship between astrocytes and vascular sprouts in the retinas of normal and knockout mice on day 17. Astrocytes degenerated in the vascular occlusion zone of the OIR mouse retina, and the loss of astrocytes was accompanied by increased GFAP reactivity in Müller cells. Furthermore, GFAP staining was relatively sparse in the knockout mouse retina compared to that of normal mice. The figure shows punctate staining at the terminals of Müller cells in the superficial vascular plexus (Figure 35). However, in the central retina of both normal and knockout mice, astrocytes formed better networks and retained their normal astrocyte / dendrite morphology after Agomir treatment (Figure 35). We then observed the remodeling of degenerated vessels by observing filopodia extending from vascular sprouts at the edges of the nonperfused area. The results showed that Agomir treatment increased the density of endothelial tip cells in both normal and knockout mouse retinas (Figure 36), and that astrocytes provided a scaffold and template for the filopodia of tip endothelial cells to extend into the occluded retina (Figure 36).
[0311] Example 8: Therapeutic effect of miR-15a-5p on laser-induced choroidal neovascularization in mice
[0312] The inhibitory effect of miR-15a-5p on neovascularization was also verified in a choroidal neovascularization model. First, a laser was used to induce choroidal neovascularization. The model construction process is shown in Figure 37. Agomir-15a-5p mimic, a mimic control, and a VEGF monoclonal antibody were injected into the vitreous cavity of mice. One week later, fundus fluorescein angiography showed a significant reduction in the area of fluorescence leakage in the Agomir-15a-5p mimic and VEGF monoclonal antibody groups compared to the control group, suggesting that both groups can inhibit choroidal neovascularization (Figures 38-39). Choroidal flat mounts from mice with choroidal neovascularization were stained with IB4 to quantify the area of neovascular clusters (Figure 40). Statistically, both the Agomir-15a-5p mimic and the VEGF monoclonal antibody groups significantly inhibited the formation of choroidal neovascular clusters (Figure 41).
[0313] In the choroidal neovascularization model, miR-15a-5p was also delivered using the virus shown in Figure 22. The nucleic acid sequence carried by the adeno-associated virus is TAGCAGCACATAATGGTTTGTG (SEQ ID NO: 9), which can be transcribed into miR-15a-5p in vivo to exert a therapeutic effect.
[0314] Seven days before the mice were modeled, adeno-associated virus containing miR-15a-5p (1×10 12 amount) and control virus (1×10 12 ). On the 7th day after the injection, the retina was sampled, and the site of infection by the adeno-associated virus was observed by frozen sections of the eyeball. The results in Figure 42 showed that the adeno-associated virus containing miR-15a-5p infected the retina and choroid, and diffuse fluorescence appeared in the retinal pigment epithelium and choroid. Subsequently, the miR-15a-5p content in the retina and choroid of each group was detected by PCR. The results are shown in Figure 43. The miR-15a-5p content in the retina and choroid of the group injected with the adeno-associated virus containing miR-15a-5p was 7 times that of the control group, indicating that the virus can successfully infect the retina and choroid and overexpress miR-15a-5p. The quantification of retinal neovascularization in mice was performed on the 7th day after laser induction. The results showed that the retinal neovascularization in the group injected with the adeno-associated virus containing miR-15a-5p was significantly reduced (Figures 44-45). The above results indicate that adeno-associated virus containing miR-15a-5p can successfully deliver miR-15a-5p into mouse retinal choroid cells and has a therapeutic effect on laser-induced retinal neovascularization in mice.
[0315] Example 8 also employed two methods for delivering miR-15a-5p: one using modified miR-15a-5p and the other using adeno-associated virus. Intraocular injection of the two substances achieved the goal of increasing miR-15a-5p levels in the retina and choroid. A laser-induced choroidal neovascularization model was employed to simulate choroidal neovascularization. This example observed the therapeutic effects of miR-15a-5p on neovascularization in this model and found that miR-15a-5p has a therapeutic effect on choroidal neovascularization.
[0316] Example 9: Therapeutic effects of miR-15a-5p on oxygen-induced retinal structural and functional damage in mice
[0317] Example 5 shows that miR-15a-5p can restore early blood perfusion of the OIR retina, which is crucial for the nutrition and development of retinal nerve cells. This example continues to evaluate the protective effect of miR-15a-5p on the retina from two aspects: retinal thickness and optic nerve function. First, H&E staining can be used to visually observe the structural changes of the retina. Figure 46 shows that the retinal structure of mice in the Agomir-15a-5p mimetic treatment group is intact, and the thickness of the outer plexiform layer (the layer indicated by the star mark) is normal, while the outer plexiform layer of mice in the VEGF monoclonal antibody group is significantly thinner. Therefore, Agomir-15a-5p mimetic can significantly improve the damage to the retinal structure and function of oxygen-induced mice. Afterwards, optical coherence tomography OCT was used to quantify the thickness of each retinal layer (Figures 47-48). The results showed that Agomir-15a-5p mimetic can significantly improve the retinal thinning of oxygen-induced mice, while the retinal thickness of the VEGF monoclonal antibody group was no significantly different from that of untreated mice, and it could not improve the retinal thinning of oxygen-induced mice (Figure 49). Retinal electrophysiology (ERG) is widely used to assess retinal function. The therapeutic effects of Agomir-15a-5p mimics on oxygen-induced retinal function in mice were observed at both early (25 days after birth) and late (42 days after birth) stages (Figure 50). Compared to the untreated normoxia group, the a-wave and b-wave amplitudes of the retinas in all oxygen-induced groups were reduced. However, treatment with Agomir-15a-5p mimics significantly increased the a-wave and b-wave amplitudes in the oxygen-induced groups. However, VEGF monoclonal antibodies had no therapeutic effect on oxygen-induced neurological damage in the mouse retina (Figure 51).
[0318] The retina is part of the nervous system, and its main function is to convert light signals into electrical signals and transmit them to the brain. The structure of the retina is the basis for normal visual function, which directly determines the patient's vision. Various fundus lesions are accompanied by loss of retinal structure and function. The oxygen-induced retinopathy model adopted in this example showed obvious retinal thinning and weakened electrophysiological function after onset. After intraocular administration of miR-15a-5p, both retinal structure and neural function were significantly improved, and were better than the VEGF monoclonal antibody group.
[0319] Example 10: Therapeutic effects of miR-15a-5p on laser-induced choroidal and retinal structural and functional damage in mice
[0320] H&E staining was used to assess the retinal interlayer structure, cell morphology, and choroidal neovascularization lesions. As shown in Figure 52, in the control group, the choroid sent new blood vessels that grew into the retinal layer, and the retina was locally bulged. The Agomir-15a-5p mimetic treatment group had less bulges and the lesions basically disappeared, while the VEGF monoclonal antibody group had a few lesions remaining. ERG was used to assess the electrophysiological function of the retina of mice with choroidal neovascularization. The results, as shown in Figures 53 and 54, showed that the Agomir-15a-5p mimetic treatment group significantly improved the retinal function damage of mice with choroidal neovascularization, while the VEGF monoclonal antibody group had no significant therapeutic effect on retinal function damage. In addition, under oxidative stress, gliosis will occur in the retina, and GFAP is an indicator of glial cell activation, representing an increase in the level of retinal inflammation. After Agomir-15a-5p treatment, the activation of GFAP in the OIR retina was significantly reduced (A, B, C, D in Figure 55), indicating that miR-15a-5p inhibits the proliferation of glial cells in the OIR retina. However, compared with the control group, VEGF monoclonal antibody treatment did not show a trend of inhibiting GFAP activation, and the trend was not statistically significant.
[0321] The laser-induced chorioretinal injury model adopted in this example also showed obvious retinal thinning and weakened electrophysiological function after the onset of the disease. After intraocular administration of miR-15a-5p, the retinal structure and neural function were significantly improved, and were better than the VEGF monoclonal antibody group.
[0322] Example 11: Therapeutic effect of miR-15a-5p on hyperoxia-induced and laser-induced retinal inflammation in mice
[0323] Oxygen-induced retinopathy in mice is accompanied by increased levels of inflammation. To investigate the therapeutic effects of miR-15a-5p on retinal inflammation in mice, retinal TNFα expression levels were measured at P17, P25, and P42. Figure 56 shows that TNFα protein expression levels were reduced in the Agomir-15a-5p mimetic group at P17, while the VEGF monoclonal antibody group had no therapeutic effect on the elevated TNFα levels in the retina. There were no statistical differences between the groups at P25 and P42. Intercellular adhesion molecule 1 (ICAM-1) is typically expressed in endothelial cells and immune cells and plays a key role in leukocyte migration and activation. Oxygen-induced ICAM-1 expression levels were elevated in the mouse retina, while ICAM-1 expression levels were decreased in the Agomir-15a-5p mimetic group (Figures 57-58). Laser-induced choroidal neovascularization in the mouse fundus was associated with increased levels of choroidal inflammation. The results in Figure 59 show that injection of Agomir-15a-5p mimetic can reduce the levels of laser-induced retinal inflammatory factors in all groups of mice, while the VEGF monoclonal antibody group has no therapeutic effect on laser-induced retinal inflammation in all groups of mice.
[0324] Fundus diseases are often accompanied by increased expression levels of inflammatory factors, which lead to aggravation of retinal and choroidal diseases and prolonged disease. TNFα and IL-1β are often classic inflammatory factors that recruit inflammatory cells to aggregate. ICAM-1 is an endothelial cell adhesion molecule that can recruit leukocytes to adhere to endothelial cells and increase vascular permeability. This example detected the levels of inflammatory factors in the retina at different treatment nodes, and the results showed that intraocular administration of miR-15a-5p can significantly reduce the expression levels of inflammatory factors in the retina and choroid. The VEGF monoclonal antibody group did not show a significant effect in improving retinal inflammation.
[0325] Example 12: miR-15a-5p targeted regulation of VEGF
[0326] MiR-15a-5p is a base sequence that regulates downstream genes by binding to the RNA of the target gene through complementary base pairing, thereby hindering the translation of the target gene into protein. This example observes the targeted regulatory effect of miR-15a-5p on VEGF through in vitro and in vivo experiments. In vitro experiments used unmodified miR-15a-5p mimics, and in vivo experiments used modified miR-15a-5p mimics (Agomir). Through complementary base pairing, it was found that miR-15a-5p can specifically bind to VEGF mRNA, so subsequent examples were verified in cells and animals respectively. Retinal pigment epithelial (RPE) cells are one of the sources of intraocular VEGF. It is known that TGF-β1 can increase the level of VEGF secreted by RPE cells in vitro. Therefore, RPE cells were transfected with a miR-15a-5p mimic and TGF-β1 was used to induce VEGF secretion. The results showed that miR-15a-5p could reduce the increase in VEGF expression induced by TGF-β1. Figure 60 shows VEGF mRNA levels, Figures 61-62 show VEGF protein levels, and Figure 63 shows VEGF protein levels in RPE cell supernatants. Figure 64 shows a dual-luciferase reporter assay. Wild-type VEGF mRNA can bind to miR-15a-5p, while mutant VEGF cannot bind to miR-15a-5p. Therefore, fluorescence is quenched only in the bound group, suggesting that miR-15a-5p can specifically regulate VEGF transcription. Figures 65 and 66 show that intravitreal injection of Agomir-15a-5p mimics can reverse hyperoxia-induced increase in VEGF expression in the mouse retina. Figure 67 shows that intravitreal injection of Agomir-15a-5p mimics can reverse laser-induced increase in VEGF mRNA expression in the mouse retina.
[0327] Example 13: miR-15a-5p can inhibit retinal ERK phosphorylation signal activation for a longer period of time than anti-VEGF
[0328] MiR-15a-5p specifically binds to VEGF mRNA and inhibits VEGF transcription. VEGF monoclonal antibodies antagonize VEGF protein, but their mechanisms differ. Therefore, when comparing the efficacy of these two treatments, it is appropriate to observe activation of VEGF downstream signaling pathways. After VEGF specifically binds to its receptor, VEGFR2, it activates endothelial cell proliferation by phosphorylating signaling pathways such as ERK. Therefore, the ERK phosphorylation signaling pathway was selected as an indicator for observation.
[0329] The schematic diagram of injection and sampling is shown in Figure 68A. The results showed that on the day of injection, P12, the retina of mice in the hyperoxia-induced group showed an enhanced phosphorylated ERK signal (Figure 68B and Figure 68I); on the first day after injection, P13, the phosphorylated ERK signal in the retina of mice in the VEGF monoclonal antibody group first showed a downward trend (Figure 68C and Figure 68J); on the second day after injection, P14, both the VEGF monoclonal antibody and Agomir-15a-5p mimetic groups showed a downward trend in phosphorylated ERK signal (Figure 68D and Figure 68K); on the fourth day after injection, P15, the ERK phosphorylation signal in the VEGF monoclonal antibody group returned to a high level, while the Agomir-15a-5p mimetic group showed a downward trend (Figure 68D and Figure 68K); on the fourth day after injection, P15, the ERK phosphorylation signal in the VEGF monoclonal antibody group returned to a high level, while the Agomir-15a-5p mimetic group showed a downward trend (Figure 68D and Figure 68K). The gomir-15a-5p mimetic group maintained a downward trend in phosphorylated ERK signals, and there was a statistical difference between the two (Figure 68 E and Figure 68 L); at the peak of neovascularization, P17 and P15, the Agomir-15a-5p mimetic group maintained a downward trend in phosphorylated ERK signals, the VEGF monoclonal antibody group had no inhibitory effect, and there was a statistical difference between the two (Figure 68 F and Figure 68 M); during the neovascularization recovery period, i.e., P20 and P25, there was no significant difference in phosphorylated ERK signals between the retinas of the various groups (Figure 68 G, Figure 68 H, Figure 68 N, and Figure 68 O). There was no significant difference in the total protein level of ERK during the above process, so the relative changes in phosphorylated ERK signals at each time period were plotted as a line graph. As can be clearly seen in Figure 68, Panel P, the phosphorylation signal of ERK in the retina of untreated mice increased from P13, gradually decreased by P17, and remained at its highest level. The VEGF monoclonal antibody group inhibited ERK phosphorylation to a greater extent than the Agomir-15a-5p mimic at P13. However, starting at P14, the Agomir-15a-5p mimic inhibited ERK phosphorylation to a greater extent than the VEGF monoclonal antibody, with statistically significant differences between the Agomir-15a-5p mimic and the VEGF monoclonal antibody group at P15 and P17. The difference between the two groups reached a peak at P17, and there was no inhibitory effect on ERK phosphorylation at P20 and P25. This suggests that miR-15a-5p, by binding to VEGF mRNA, can more sustainably inhibit the ERK signaling pathway, thereby reducing pathological neovascularization.
[0330] Example 14: miR-15a-5p targeted regulation of Smad2 reduces retinal endothelial cell mesenchymal transition
[0331] Through base pairing, it was found that miR-15a-5p can specifically bind to Smad2 mRNA, so the subsequent examples were verified in cells and animals respectively. In vitro experiments used unmodified miR-15a-5p mimics (mimics), and in vivo experiments used modified miR-15a-5p mimics (Agomirs). First, miR-15a-5p mimics and inhibitors were transfected into retinal endothelial cells. PCR (Figure 69) and Western Blot (Figures 70-71) experiments showed that miR-15a-5p can inhibit the RNA and protein expression levels of Smad2, while the miR-15a-5p inhibitor can promote the RNA and protein expression levels of Smad2. This suggests that miR-15a-5p can regulate the expression of Smad2. To confirm the direct binding of miR-15a-5p to Smad2, dual luciferase reporter assay was used for verification (Figure 72). The results showed that compared with the control group, the miR-15a-5p mimic significantly reduced the luciferase activity of the wild-type Smad2 vector and had no effect on the luciferase activity of the mutant Smad2. Therefore, miR-15a-5p inhibits the transcription and expression of Smad2 by binding to its mRNA, indicating that Smad2 is a direct regulatory target of miR-15a-5p.
[0332] Ocular fundus diseases such as diabetic retinopathy, neovascular retinal disease, choroidal neovascularization, and proliferative vitreoretinopathy are all accompanied by pathological changes in retinal fibrosis. Smad2, as a component of the TGF-β signaling pathway, is a typical pro-fibrotic pathway protein. Therefore, to verify whether miR-15a-5p can inhibit retinal fibrosis by inhibiting Smad2, we used TGF-β1 to stimulate retinal endothelial cells to induce endothelial-mesenchymal transition (EndoMT) to simulate retinal fibrosis. Then, we transfected miR-15a-5p mimics into the cells to observe the inhibitory effect of miR-15a-5p mimics on EndoMT.
[0333] Immunofluorescence staining (Figures 73-74) and Western blot (Figures 75-76) experiments revealed that TGF-β1-stimulated endothelial cells significantly increased the expression of fibrotic markers vimentin and α-SMA, while decreasing the expression of the endothelial cell marker CD31. This suggests that TGF-β1 induces endothelial cell-to-fibroblast transformation, or EndoMT. Transfection with a miR-15a-5p mimic reversed the TGF-β1-induced increases in vimentin and α-SMA expression and decreases in CD31 expression. Therefore, miR-15a-5p can reverse TGF-β1-induced EndoMT by inhibiting Smad2 phosphorylation and total Smad2 expression (Figures 77-78).
[0334] Example 15: miR-15a-5p targeted regulation of Smad2 reduces retinal Müller cell fibrosis
[0335] Müller cells are specialized glial cells that are present throughout the retina. They maintain the normal structure and function of the retina and are involved in a variety of pathological processes, particularly proliferative fundus lesions such as retinal neovascularization and diabetic retinopathy. Culturing Müller cells in vitro is one approach to studying these proliferative fundus lesions. TGF-β2 can stimulate Müller cells to exhibit a fibrotic phenotype in vitro. The results in Figures 79 and 80 show that 1 ng / mL of TGF-β2 can cause Müller cell activation accompanied by increased expression of fibrosis-related proteins. Therefore, this example used 1 ng / mL of TGF-β2 for modeling. Müller cells were transfected with miR-15a-5p mimics and a mimic control, and then co-cultured with 1 ng / mL of TGF-β2. The results showed that Müller cells transfected with the miR-15a-5p mimic had reduced GFAP expression and reduced expression of fibrosis-related proteins (Figures 81 and 82). Further immunofluorescence analysis was performed, using the Müller cell marker GS to identify Müller cells (Figure 83). Transfection with the mimic reversed Müller cell activation and fibrosis (Figure 84). Furthermore, transfection with a miR-15a-5p mimic reduced the expression of inflammatory factors, including TNF-α and MCP1, in Müller cells (Figures 85 and 86).
[0336] Since miR-15a-5p has been shown to target Smad2 and reduce TGFβ signaling pathway activation in retinal endothelial cells, it was validated in Müller cells. Figure 87 shows that the total Smad2 expression level in Müller cells transfected with miR-15a-5p mimics was reduced, and the phosphorylation signal was weakened (Figure 88). Therefore, miR-15a-5p can target Smad2 expression and reduce retinal Müller cell fibrosis.
[0337] Example 16: miR-15a-5p targeted regulation of Smad2 reduces hyperoxia-induced retinal fibrosis in mice
[0338] Agomir-15a-5p mimics, a mimic control, and a VEGF monoclonal antibody were injected into the vitreous cavity of mice induced by hyperoxia. Eyeballs of the mice were frozen and sectioned at P17, and protein was extracted and analyzed by Western blot. Figure 89 shows the colocalization of α-SMA and retinal blood vessels in the retina. The hyperoxia control group showed higher α-SMA expression and colocalization with blood vessels, while the group injected with the Agomir-15a-5p mimic showed lower α-SMA expression and less retinal colocalization. Figure 90 shows the localization of fibronectin expression and retinal blood vessels. The hyperoxia control group showed higher fibronectin expression and colocalization with blood vessels, while the group injected with the Agomir-15a-5p mimic showed lower fibronectin expression and less retinal colocalization. The group injected with the VEGF monoclonal antibody showed higher fibronectin expression. Figure 91 shows the localization of α-SMA expression and activated Müller cells in the retina, with GFAP indicating activated Müller cells. The results showed that α-SMA colocalized more significantly with activated Müller cells in the retina in the hyperoxia control and VEGF monoclonal antibody groups. This suggests that the Agomir-15a-5p mimic can inhibit retinal fibrosis, while VEGF monoclonal antibody treatment exacerbates retinal fibrosis. Western blot analysis results, shown in Figure 92, further confirm that miR-15a-5p can reduce the expression of retinal fibrosis proteins and alleviate retinal fibrotic changes. However, VEGF monoclonal antibody treatment had no therapeutic effect on retinal fibrosis.
[0339] Example 17: Safety Assessment of miR-15a-5p on Oxygen-Induced Mouse Development
[0340] After Examples 5 and 9 confirmed the therapeutic effect of intravitreal injection of Agomir-15a-5p mimics on oxygen-induced neovascularization in mice, their drug safety should be evaluated to determine whether this treatment regimen has adverse effects on the growth, development, metabolism, and vital organs of mice. Figure 93, Panel A, shows the weight changes of mice from P12 (12 days after birth), the day of administration, to P42 (42 days after birth), when the mice are essentially adults. The results showed that from 15 days after birth, the weight growth rate of mice in the normoxia group was significantly higher than that of the three groups of mice in the hyperoxia group. However, from administration to adulthood, there was no significant difference in the weight growth rate of the three groups of mice in the hyperoxia group (Figure 93, Panel A). Therefore, intravitreal injection of Agomir-15a-5p mimics did not have an adverse effect on the growth and development of mice in the hyperoxia group. To further investigate the safety of intravitreal injection of the Agomir-15a-5p mimetic, serum was collected from mice at P17, P25, and P42 for analysis of indicators such as total cholesterol, triglycerides, creatinine, and urea nitrogen, and liver and kidney function was assessed. As shown in Figure 93 (B), the plasma color of mice in the VEGF monoclonal antibody-treated group differed from that of the other groups, suggesting that VEGF monoclonal antibody treatment may affect lipid metabolism in mice. As shown in Figure 93 (C), serum creatinine levels were significantly lower in the three hyperoxia-treated groups compared to the normoxia group at both P17 and P25, but no significant differences were observed between groups, possibly due to lower body weight. Figure 93 (D) demonstrates that at P17, serum urea levels were significantly higher in the VEGF monoclonal antibody-treated group compared to the other groups. At P25, serum urea levels were significantly higher in the hyperoxia control group, while no significant differences were observed between the Agomir-15a-5p mimetic-treated and normoxia groups. Figure 93 E shows the results of plasma triglycerides. Except for P17, the serum triglyceride level of mice in the VEGF monoclonal antibody treatment group was significantly increased, and there was no significant difference between the other groups. Figure 93 F shows the trend of changes in total cholesterol. At P17, the total cholesterol level expression in the hyperoxia group was higher than that in the normoxia group, but there was no significant difference between the hyperoxia groups. In addition, H&E staining was used to observe the liver and kidney structures of P17, P25 and P42 mice (Figure 93 G and Figure 93 H). The above results show that intravitreal injection of Agomir-15a-5p mimics will not have adverse effects on the growth, development, metabolism and organs of mice in the hyperoxia group. Intraocular injection of VEGF monoclonal antibodies will cause abnormal blood lipid metabolism in mice in the model group.
[0341] Example 18: Safety Assessment of miR-15a-5p on Normal Mouse Development and Retina
[0342] According to the above treatment plan, mice without modeling were injected into the vitreous cavity. The weight of each group of mice was tested, and it was found that the weight of the VEGF monoclonal antibody group showed a downward trend from P21. At P24, the weight loss was significant, with statistically significant differences from the other three groups, and continued until P42. However, the Agomir-15a-5p mimetic did not affect the weight of normal mice (Figure 94, Panel A). Similarly, serum of mice was collected at three time points, P17, P25, and P42, and indicators such as creatinine (Figure 94, Panel B), urea nitrogen (Figure 94, Panel C), triglycerides (Figure 94, Panel D), and total cholesterol (Figure 94, Panel E) were observed to evaluate the liver and kidney function of lipid metabolism in each group of mice. It was found that except for the VEGF monoclonal antibody group, which had an increased triglyceride level compared with the normoxia group at P17, there was no difference in the other groups, which indicates that VEGF monoclonal antibody affects the triglyceride metabolism of mice. After intravitreal injection of fluorescent molecule (CY3) labeled Agomir-15a-5p mimics, the liver and kidneys of mice were tested. The results showed no obvious fluorescence in the liver and kidneys, indicating that the Agomir-15a-5p mimics did not remain in the liver and kidneys (Figure 94, Figure F). Tissue sections of the mouse kidneys (Figure 94, Figure G) and livers (Figure 94, Figure H) were stained with H&E, and the results showed no obvious abnormalities. Intravitreal injection of drugs was performed on mice without modeling to observe whether intravitreal injection of Agomir-15a-5p mimics had side effects on the eyes and growth and development of normal mice. OCT results showed that Agomir-15a-5p mimics had no effect on retinal thickness, but the retinas of mice in the VEGF monoclonal antibody group were thinner (Figure 94, Figure J, Figure 94, Figure K). GFAP staining showed that intravitreal injection of Agomir-15a-5p mimics did not cause activation of glial cells (Figure 94, Figure L, Figure 94, Figure M). This indicates that intravitreal injection of VEGF monoclonal antibodies can lead to developmental delay, abnormal lipid metabolism and retinal thinning in mice.
[0343] Example 19: Protective effect of miR-15a-5p on retinal nerve damage in diabetic mice
[0344] Diabetic patients have high blood sugar levels, which cause irreversible damage to the nervous system. The visual function of diabetic patients declines significantly. In this example, spontaneous diabetic model mice (leptin knockout mice) are selected as a model of retinal neurodegeneration to study and observe the protective effect of intraocular injection of miR-15a-5p on neurodegeneration. Agomir-15a-5p mimics were injected into the vitreous cavity of 12-week-old mice, and the same number of mice were injected into the vitreous cavity with mimics as controls. Retinal electrophysiology was used to detect the retinal function of diabetic mice at 16 weeks. The results showed that Agomir-15a-5p mimics can significantly improve the amplitude intensity of retinal photoreceptor cells (Figure 95, Figure 96 and Figure 98) and bipolar cells (Figure 95 and Figure 97) of diabetic mice compared to their controls, that is, Agomir-15a-5p mimics have a protective effect on retinal nerve damage in diabetic mice.
[0345] Example 20: Loss of miR-15a-5p leads to abnormal vascular development in mice
[0346] After birth, the mouse retinal blood vessels emanate from the optic disc, spreading radially from the inner surface of the retina, gradually forming a superficial vascular network that covers the entire retina. This network then develops deeper, forming a complete retinal vascular system. During this period, by P7, the superficial vessels have differentiated into trunks and branches, covering 80% of the retinal area, and begin to develop deeper. By P9, the superficial vessels completely cover the retina, while the deep vessels gradually cover 50%. Simultaneously, astrocytes are closely associated with the development of the retinal vascular network. Astrocytes also emanate from the optic disc and gradually spread from the optic disc to the periphery of the superficial inner retina. Individual astrocytes exhibit a star-shaped structure, and overall, they form a network-like structure similar to that of the vascular network. They develop earlier than blood vessels, providing a template for retinal vascular development. In this example, we used miR-15a-5p knockout mice to observe the development of retinal blood vessels and astrocytes at P7 and P9. Figure 99 shows that 7 days after birth, the superficial blood vessels in miR-15a-5p knockout mice were retarded in development, with their coverage of the retina lower than that of normal mice, with statistically significant differences (Figure 99A and Figure 99B). This suggests that miR-15a-5p deficiency slows the development of superficial retinal blood vessels in mice. Furthermore, the total length, branch length, and number of nodes formed by intersecting vessels in the superficial vascular network of miR-15a-5p knockout mice were all less than those in normal mice (Figure 99C, Figure 99D, and Figure 99E), indicating that miR-15a-5p deficiency leads to a decrease in the regularity of the vascular network. Figure 99F is a representative image of co-staining of blood vessels and astrocytes. Despite the lack of vascular perfusion in the peripheral area of normal mice, a large number of astrocytes still formed a network structure, but astrocytes were absent in the peripheral area of knockout mice. Statistically, the number of nodes and total length of the network structure composed of GFAP-positive astrocytes in the knockout mouse retina were less than those in normal mice (Figure 99, Panels G and H). The overlap between the vascular network and the network structure composed of astrocytes in the knockout mouse retina was lower than that in normal mice (Figure 99, Panel I).
[0347] Nine days after birth, the superficial vascular network basically covers the retina, but the superficial vascular network of the knockout mice is less regular (Figure 100A), and the number of superficial vascular nodes, the number of superficial vascular meshes, the total length of superficial vessels, and the total length of superficial vascular branches are all lower than those of normal mice (Figure 100C, Figure 100D, Figure 100E, and Figure 100F). The development of deep blood vessels is shown in Figure 100B. The deep vascular network of the knockout mice covers less retina than that of normal mice (Figure 100G). Therefore, the absence of miR-15a-5p will lead to delayed development of superficial and deep retinal blood vessels, abnormal development of astrocytes, and the loss of connection between the vascular network and the astrocyte network. That is, miR-15a-5p has an important regulatory role in vascular development.
[0348] Among the above 20 examples, Example 1 and Example 4 show that unmodified miR-15a-5p or modified miR-15a-5p has biological activity, can be absorbed by cells in vitro, or absorbed by retinal cells in vivo, and quickly exert biological effects. Example 2 and Example 3 show that in vitro, miR-15a-5p can inhibit pathological neovascularization. Examples 5-11 show that in vivo, through intraocular administration, miR-15a-5p can inhibit pathological neovascularization, promote the recovery of non-perfused areas, reduce the expression of retinal inflammatory factors and promote nerve damage repair. VEGF is a classic angiogenesis-promoting factor that participates in the progression of various fundus diseases. Among them, Examples 6 and 7 show that miR-15a-5p can rescue astrocytes and provide a template for vascular apical cells. Compared with VEGF monoclonal antibodies, it can significantly promote the recovery of non-perfused areas. Vascular perfusion is crucial for the survival of nerve cells. Example 12 demonstrates that miR-15a-5p can directly target and regulate VEGF mRNA expression levels. Example 13 further compares the persistence of miR-15a-5p and VEGF monoclonal antibodies in inhibiting the retinal neovascularization signaling pathway. The results show that miR-15a-5p can exert a more sustained inhibitory effect. Ocular fundus diseases such as diabetic retinopathy, neovascular retinal disease, choroidal neovascularization, and proliferative vitreoretinopathy are accompanied by pathological changes in retinal fibrosis. Smad2, as a link in the TGF-β signaling pathway, is a typical pro-fibrotic pathway protein. Examples 14-16 demonstrate that miR-15a-5p inhibits the occurrence of retinal fibrosis by inhibiting Smad2. Examples 17-18 evaluate the effects of intraocular injection of miR-15a-5p and VEGF monoclonal antibodies on oxygen-induced mouse development and normal mouse development. The results show that VEGF monoclonal antibodies can cause weight loss and dyslipidemia in normal mice, while miR-15a-5p has no adverse effects on mouse development. Example 19 shows that miR-15a-5p can alleviate retinal neurodegeneration in diabetic mice. Example 20 shows that the absence of miR-15a-5p leads to delayed development of superficial and deep retinal blood vessels in mice, abnormal development of astrocytes, and further leads to loss of connection between the vascular network and the astrocyte network, affecting retinal development. In other words, miR-15a-5p has an important regulatory effect on vascular development. In summary, miR-15a-5p or modified miR-15a-5p has a clear effect in the treatment of fundus diseases and has very good application and research value in the field of biomedicine.
[0349] Example 21: Therapeutic effect of miR-15a-5p mutant on retinal neovascularization
[0350] Example 1-20 demonstrates that miR-15a-5p or modified miR-15a-5p has a clear effect in treating fundus diseases. This example further mutates miR-15a-5p to determine the role of miR-15a-5p mutants in treating fundus diseases. The mutation sites are shown in Table 4, where the bold sequence is the seed sequence (the sequence that must be included to treat the disease), and the underlined sequence is the mutant sequence, which mutates 1, 2, 3, and 5 sites respectively. The mutant sequence was then used to treat the retinal neovascularization model. The results are shown in Table 4 and Figure 101. The wild-type sequence can inhibit neovascularization by 74.8%, and the non-seed region mutant sequence can still achieve a similar effect of inhibiting neovascularization. Therefore, this example confirms that the miR-15a-5p seed sequence has a regulatory effect on the two.
[0351] Table 4
[0352] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the scope of protection of the present invention.
[0353] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any appropriate manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. Use of miRNA and / or modified miRNA and / or vectors containing nucleic acids transcribed into miRNA in the preparation of products for treating and / or preventing fundus diseases, wherein the nucleotide sequence of the miRNA includes ACGACGAU (SEQ ID NO: 10).
2. The use according to claim 1, characterized in that: The nucleotide sequence of the miRNA includes SEQ ID NO: 10, and has more than 60% identity with the nucleotide sequence of SEQ ID NO: 1, or contains a nucleotide sequence in which one or more nucleotides are substituted, deleted or inserted.
3. The use according to claim 2, characterized in that: The nucleotide sequence of the miRNA has 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95% or more identity with the nucleotide sequence of SEQ ID NO: 1, or contains a nucleotide sequence with no more than ten nucleotides substituted, deleted or inserted.
4. The use according to claim 1, characterized in that: The nucleotide sequence of the miRNA is SEQ ID NO:
1.
5. The use according to claim 1, characterized in that: The nucleic acid transcribed into miRNA comprises TAGCAGCA (SEQ ID NO: 11).
6. The use according to claim 1, characterized in that: The nucleic acid transcribed into miRNA comprises SEQ ID NO: 11, and has more than 60% identity with the nucleotide sequence of SEQ ID NO: 9, or comprises a nucleotide sequence in which one or more nucleotides are substituted, deleted or inserted.
7. The use according to claim 1, characterized in that: The nucleic acid transcribed into miRNA is SEQ ID NO:
9.
8. The use according to claim 1, characterized in that: The fundus disease is selected from one or more of vitreous lesions, retinal lesions, optic neuropathy or choroidal lesions.
9. The use according to claim 1, characterized in that: The fundus disease is selected from one or more of retinopathy of prematurity, retinal neovascularization, choroidal neovascularization or diabetic retinopathy.
10. The use according to claim 1, characterized in that: The sequence of the miRNA contains modifications, such as modifications made at the bases.
11. The use according to any one of claims 1 to 10, characterized in that: The vector is a viral vector or a non-viral vector.
12. The use according to claim 11, characterized in that: The viral vector includes one or more of a lentiviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a poxvirus vector or a herpesvirus vector.
13. The use according to claim 11, characterized in that: The non-viral vector comprises one or more of liposomes, lipid nanoparticles, polymers, polypeptides, antibodies, aptamers or N-acetylgalactosamine.
14. The use according to claim 1, characterized in that: Modified miRNAs include modifications made at the bases.
15. The use according to claim 10 or 14, characterized in that: The modification on the base includes one or more of cholesterol modification at the 3' end, two sulfide skeleton modification at the 5' end, four sulfide skeleton modification at the 3' end, or full-chain methoxy modification.
16. The use according to claim 1, characterized in that: The product comprises a sense strand and an antisense strand, wherein the sense strand comprises SEQ ID NO: 1 or a nucleotide sequence having more than 60% homology to the nucleotide sequence of SEQ ID NO: 1 or comprising substitution, deletion or insertion of one or more nucleotides, and the antisense strand comprises SEQ ID NO: 6 or a nucleotide sequence having more than 60% homology to the nucleotide sequence of SEQ ID NO: 6 or comprising substitution, deletion or insertion of one or more nucleotides; Preferably, the antisense strand contains base modifications.
17. A vector comprising a nucleic acid transcribed into miRNA, characterized in that The nucleotide sequence of the miRNA includes SEQ ID NO:
10.
18. The carrier according to claim 17, characterized in that The miRNA nucleotide sequence includes SEQ ID NO: 10, and has more than 60% identity with the nucleotide sequence of SEQ ID NO: 1 or contains a nucleotide sequence of substitution, deletion or insertion of one or more nucleotides; Preferably, the sequence of the miRNA is SEQ ID NO:
1.
19. The carrier according to claim 17, characterized in that The nucleic acid transcribed into miRNA comprises TAGCAGCA (SEQ ID NO: 11).
20. The carrier according to claim 17, characterized in that The nucleic acid transcribed into miRNA comprises SEQ ID NO: 11, and has more than 60% identity with the nucleotide sequence of SEQ ID NO: 9, or comprises a nucleotide sequence in which one or more nucleotides are substituted, deleted or inserted.
21. The carrier according to claim 17, characterized in that The nucleic acid transcribed into miRNA is SEQ ID NO:
9.
22. The carrier according to claim 17, characterized in that The vector is a viral vector or a non-viral vector; Preferably, the viral vector comprises one or more of a lentiviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a poxvirus vector or a herpesvirus vector; Preferably, the non-viral vector comprises one or more of liposomes, lipid nanoparticles, polymers, polypeptides, antibodies, aptamers or N-acetylgalactosamine.
23. A drug or a pharmaceutical composition, characterized in that The drug or pharmaceutical composition comprises miRNA or its mimics, modified miRNA or the vector according to any one of claims 17 to 22, and pharmaceutically acceptable excipients; The nucleotide sequence of the miRNA includes ACGACGAU (SEQ ID NO: 10).
24. The drug or pharmaceutical composition according to claim 23, characterized in that The miRNA nucleotide sequence includes SEQ ID NO: 10, and has more than 60% identity with the nucleotide sequence of SEQ ID NO: 1 or contains a nucleotide sequence of substitution, deletion or insertion of one or more nucleotides; Preferably, the nucleotide sequence of the miRNA is SEQ ID NO:
1.
25. The drug or pharmaceutical composition according to claim 23, characterized in that The modified miRNA includes modifications made on the bases; preferably, the modifications made on the bases include one or more of cholesterol modification at the 3' end, two thio-skeleton modifications at the 5' end, four thio-skeleton modifications at the 3' end, or full-chain methoxy modification.
26. A method for treating and / or preventing fundus diseases, characterized in that: The method comprises administering to a subject in need thereof an effective amount of a miRNA, a miRNA mimic, a modified miRNA, a vector according to any one of claims 17 to 22, or a drug or pharmaceutical composition according to any one of claims 23 to 25; Wherein, the nucleotide sequence of the miRNA includes ACGACGAU (SEQ ID NO: 10).
27. The method according to claim 26, characterized in that The fundus disease is selected from one or more of vitreous lesions, retinal lesions, optic neuropathy or choroidal lesions.
28. The method according to claim 26, characterized in that The fundus disease is selected from one or more of retinopathy of prematurity, retinal neovascularization, choroidal neovascularization or diabetic retinopathy.
29. The method according to claim 26, characterized in that The miRNA nucleotide sequence includes SEQ ID NO: 10, and has more than 60% identity with the nucleotide sequence of SEQ ID NO: 1 or contains a nucleotide sequence of substitution, deletion or insertion of one or more nucleotides; Preferably, the nucleotide sequence of the miRNA is SEQ ID NO:
1.
30. The method according to claim 26, characterized in that The miRNA or its mimic comprises a sense strand and an antisense strand, wherein the sense strand comprises SEQ ID NO: 1 or a nucleotide sequence having more than 60% homology with the nucleotide sequence of SEQ ID NO: 1 or comprising substitution, deletion or insertion of one or more nucleotides, and the antisense strand comprises SEQ ID NO: 6 or a nucleotide sequence having more than 60% homology with the nucleotide sequence of SEQ ID NO: 6 or comprising substitution, deletion or insertion of one or more nucleotides.
31. The method according to claim 26, characterized in that Modified miRNAs include modifications made at the bases; Preferably, the modification of the base includes one or more of cholesterol modification at the 3' end, two sulfide backbone modifications at the 5' end, four sulfide backbone modifications at the 3' end, or full-chain methoxy modification.
32. The method according to claim 26, characterized in that The site of administration can be an intraocular space or cavity of the subject; for example, one or more of the aqueous humor in the anterior chamber, the suspensory ligament, the ciliary body, the ciliary body and muscle, the lens or iris, the vitreous body, the retina, the choroid or the optic nerve.
Citation Information
Patent Citations
Method For Diagnosis And Prognosis Of Chronic Heart Failure
CN107683341A
Use of umbilical cord blood derived exosomes for tissue repair
CN109414459A
Application of miRNA in treating cardiac hypertrophy
CN111184734A
Application of plasma small extracellular vesicle miR-431-5p
CN111394447A
Gene medicine for preventing and treating neovascular eye diseases
CN113481237A
